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Exposure to ionizing radiation is an important medical concern because it can lead to 
health problems including cancer and cardiovascular issues. In space, astronauts are 
exposed to ionizing radiation that is not experienced by those who remain on Earth. This 
radiation can cause health problems such as cardiovascular disease. One way this can 
happen is through the creation of reactive oxygen species, which can activate TGF-β1, 
contributing to fibrosis or other cardiovascular problems.  Antioxidants can be a potential 
pharmacological mitigator of these excess reactive oxygen species because of their ability 
to neutralize reactive oxygen species. One such antioxidant with potential as a mitigator 
for radiation induced cell and tissue damage is curcumin, but is quickly excreted by the 
body because it is a hydrophobic molecule with a short half-life. In order to retain 
therapeutically relevant curcumin levels in the body, curcumin needs to be delivered by a 
drug delivery vehicle. The work presented here examines mice irradiated with 56Fe 
radiation, to mimic space radiation. These mice were treated with a drug delivery vehicle 
containing curcumin or a saline sham prior to radiation. Two weeks after radiation, the 
mice were sacrificed and the hearts and aortas were studied. To examine the effects of 
radiation on the mouse cardiovascular system, the tissues were evaluated with an aortic 
outgrowth assay, ROS assay, Masson’s trichrome staining, hematoxylin and eosin 
staining, and wall thickness studies. Statistically, the only significant tissue changes from 
56Fe radiation were noted in the thickening of the right ventricle and in the reduction of 
cardiac muscle per nuclei in the hematoxylin and eosin staining also in the right ventricle. 
The only significant results of the drug treatments were in the reduction of thinning of the 
left ventricle by the Alb/CCM and CCM treatments.  There were trends of thinning of the 
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left ventricle and thickening of the aortas as a results of the 56Fe radiation. There were 
drug treatment trends with Alb/CCM leading to the largest outgrowth of the aorta and all 
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Exposure to radiation can occur with medical treatment such as radiotherapy for breast 
cancer or Hodgkin’s lymphoma [1-4], in areas of occupational exposure such as nuclear or 
radiation workers [5, 6], or during manned space flight, such as Moon or Mars missions[7-9]. 
When astronauts are on missions that involve leaving the protection from the Earth’s 
magnetosphere, they are exposed to higher levels of ionizing radiation [10].The high energy type 
of ionizing radiation is more dangerous than non-ionizing radiation and can result in increased 
risks of cancer and DNA damage as well as cardiovascular problems [10]. . Ionizing radiation 
includes gamma rays, x-rays, and galactic cosmic radiation (GCR), which is common during 
spaceflight. About 1% of GCR are a type of highly charged ion called High Charged Energy 
(HZE) particles, which can be of many elements such as carbon, iron, or nickel nuclei. Of these 
HZE particles seen in space, iron, 56Fe ions, give the largest dose equivalent, which is an 
expression of radiation dose in terms of biological effect based on the effect of gamma radiation. 
Thus,  56Fe  radiation is the most important biologically and important to study for understanding 
spaceflight radiation exposure[11]. Since there are many different types of radiation varying 
degrees of biological damage, dose equivalent is used to represent the damage and is measured in 
Sievert (Sv). Conversely, the absorbed dose of radiation is measured in Gray (Gy). Of the GCR, 
HZE particles are the most dangerous, since they have the strongest ability to pass thorough 
matter and ionize atoms as they pass. There are also risks of solar particle events (SPE) during 
space travel [8]. NASA calculated the radiation dose for astronauts as they leave the Earth’s 
magnetosphere. For the Apollo 14 mission (9 day mission to the moon) the radiation dose was 
11.4 mSv, while for a 3 year Mars mission, the estimated radiation dose would be 1200 mSv. 
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There are also possibilities of solar events which would increase the radiation dose[12]. The 
NASA career exposure limit for astronauts is between 1 and 4 Sv depending on age and gender, 
with younger people having lower limits since they are likely to be exposed to more radiation 
through the rest of their lives[10]. The Mars mission alone would surpass the astronaut’s career 
exposure limit of 1. The career exposure limit is based upon a maximum 3% increase in risk of 
cancer mortality. The longer the mission and the deeper into space the astronauts go, the more 
important it is to develop proper protection for the astronauts’ health from radiation exposure. 
The main ways to reduce exposure to radiation from manned space missions are by 
limiting astronaut time in space and using shielding[13, 14]. Future missions to Mars will extend 
the tine in space instead of limiting the time. In addition, only so much shielding can be added to 
the spaceship due to weight and cost concerns for the spaceship. Another option is a 
pharmacological approach to minimize damage to the cells and tissue from the radiation 
exposure. If the exposure cannot be prevented, minimizing the resultant damage is a promising 
approach.   
 Understanding molecular changes in cells can aid in the development of drugs to mitigate 
radiation damage. Ionizing radiation is known to cause reactive oxygen species (ROS), which are 
chemically reactive molecules (free radicals) that contain oxygen such as superoxide anions, 
hydroxyl radicals, and hydrogen peroxide. ROS serve as signaling molecules under normal 
physiological conditions [15]. Intracellular ROS are produced largely by the mitochondria as the 
mitochondria use oxygen to produce ATP. The main ROS produced by mitochondria is 
superoxide, produced by a 1 electron reduction of O2.[16] Oxygen is used in the electron 
transport chain, as oxygen in reduced by electrons donated from NADH and FADH2 and then 
turned to water. If the electrons leak out early to oxygen, superoxide is formed [17]. This usually 
3 
 
occurs at complex I or complex III. Whether or not superoxide is produced and how quickly 
depends on concentrations of enzyme containing electron carriers that are transiently in a redox 
form and able to react with O2. [16] If there is a high NADH/NAD
+ ratio, it can cause superoxide 
production in complex 1 due to electron leakage. If there is a reduced CoQ pool and Qi site 
inhibited by antimycin, superoxide production occurs in complex III [16] 
There are also ROS generated by phagocytic cells to fight off infection. ROS can also 
serve as second messengers in signal transduction pathways in the body[18]. A rise in ROS 
levels leads to cellular damage as well as the activation of signaling pathways and has been 
linked to diseases such as atherosclerosis. There is a natural antioxidant defense system of the 
body that scavenges excessive ROS. The ROS and antioxidant levels stay in a balance, but if the 
formation of ROS outpaces the degradation by antioxidants, oxidative stress will result. 
Exposure to radiation increases ROS levels, causing DNA damage as well as long term effects 
on mitochondrial functions, and results in activation of metabolic pathways [19]. Along with the 
general damage to the cells that ROS can cause, ROS can activate other biologically active 
molecules such as growth factors like TGF-β, which can lead to fibrosis of tissues [20].  
TGF-β1:  
Transforming growth factor beta 1 (TGF-β1) is a cytokine mostly implicated in wound 
healing and in fibrosis [21]. TGF-β1 has a role in the activation of fibroblast, promotion of 
fibrosis, and formation of scar tissue [22]. Others have demonstrated radiation increased ROS 
and subsequent activation of TGF-β1, in mouse bone marrow and mammary glands and in cells 
[23, 24]. Excess TGF-β1 is linked to progressive fibrosis via the deposition of collagen and other 
extracellular matrix (ECM) components. TGF-β1 can directly affect the health of the 
cardiovascular system, causing excess ECM production in the heart and arteries [25].  
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Radiation Effects on the Cardiovascular System:  
One system affected by ionizing radiation is the cardiovascular system [3, 5, 7, 26] with 
an increased risk of myocardial infarction, coronary heart disease, and atherosclerosis[3]. Both 
gamma radiation (at doses of 0, 50, 160, and 500 cGy) and HZE 56Fe radiation (at doses of 0, 
0.5, and 1 Gy) have been shown to cause impaired angiogenesis in rats, which indicated poor 
vascular health [11, 27]. Radiation exposure also increased the stiffness of the blood vessels 
resulting in increased blood pressure, decreased endothelial function, and atherosclerosis [27]. 
Terrestrial ionizing radiation from radiotherapy has also shown vessel thickening in clinical 
settings[28]. Biopsies were taken of arteries at a mean of 4 years after irradiation (with a range of 
3 months to 26 years) from patients undergoing free-flap reconstruction surgery, and the 
thickening of the intima was found by comparing the intima thickness to the media thickness. 
The ratio of intima thickness to media thickness was larger in cases of radiation, with the largest 
effects observed in those receiving the surgery longer after the initial radiation [28]. The main 
tissue protein related to stiffness is collagen, while the protein most related to flexibility in tissue 
is elastin. The levels of these proteins help determine the overall mechanical properties of the 
arteries or heart. For example, in mice with cardiomyopathy, ventricular thickening was shown 
to be due to oxidative stress, which resulted in higher expression of fibrosis markers and of 
collagen [29].  
Antioxidants:  
The body’s natural defense against ROS is antioxidants, which can be produced by cells 
or found in external sources. One antioxidant is curcumin, derived from the spice turmeric and 
shown to have anti-carcinogenic effects, anti-proliferative effects, antioxidant effects, anti-
inflammatory effects, and anti-angiogenic effects as well as an ability to repair DNA [30-32]. 
Curcumin has the ability to reduce oxidative stress, as well as to inhibit the transcription of genes 
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that relates to inflammatory responses and modulate the paths of growth factors such as TGF-β1 
[33]. Curcumin has been shown to be non-toxic at up to 8g/day in humans [34]. However 
curcumin is unstable with degradation rates dependent on pH [30]. Given its hydrophobicity, 
curcumin has poor update in the body when administered orally. In addition, orally administered 
curcumin is quickly metabolized and excreted in the urine and feces.  Intravenous administration 
of curcumin is quickly removed in the bile [30]. Thus, curcumin has strong potential as an 
antioxidant for mitigation of radiation induced damage, but it has low bioavailability in vivo.  
Nanoparticles have been shown as a solution to enhance the bioavailability curcumin [31, 
35]. A curcumin-chitosan polymer was able to stay stable in water for over 30 days as compared 
to the 30 minutes that would occur with curcumin alone [35]. Phospholipid vehicles have been 
shown to extend the bioavailability of orally delivered curcumin in mice. The maximum 
concentration of curcumin was increased from 266.70 ng/ml to 600.93 ng/ml  and the duration of 
the curcumin increased from 1.62 hours to 2.33 hours [36]. Albumin nanoparticles have also 
been tested for delivery of curcumin, with resulting higher accumulation in tissue and detectable 
amounts of curcumin retained in the tissue after 4 hours [37]. 
Previous Work:  
Our group has fabricated three novel drug delivery systems for curcumin: albumin, lipids, 
and chitosan. Albumin, in this case Human Serum Albumin, is the main protein of human blood 
plasma. Albumin is a common drug delivery vehicle and has been shown to bind to curcumin, as 
have lipids and chitosan [35, 38, 39]. Lipids are biological substances including fats that are 
soluble in nonpolar solvents. Chitosan is a polysaccharide made by treating chitin from 
crustacean shells with an alkaline. Chitosan was bonded covalently to curcumin to make a 
product called Chitocurc which provided a burst release after exposure to radiation [35]. 
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Albumin, fusogenic lipids, and chitosan all release curcumin at various rates: lipids-minutes, 
albumin-hours, chitosan-days. The specific release times are provided in Table 2. 
A mouse model was developed to test the three nanoparticle drug delivery vehicles, 
during which the mice the nanoparticles were injected via the tail vein and then the mice were 
exposed to 0 or 4 Gy cesium-137 γ radiation. Ten days later the mice were sacrificed and the 
tissues were harvested. Each of the three drug delivery vehicles demonstrated some protective 
effects. ROS in bone marrow was higher in irradiated mice than non-irradiated. The mice 
receiving particle treatments still had increased ROS compared to non-irradiated mice, but ROS 
levels were less than irradiated mice treated with saline. The treatment with the lowest ROS was 
Chitocurc. Radiation also damaged hematopoietic progenitor cells, and the lipid vesicle 
treatment provided the most protection as measured by increased number of bone marrow 
colonies. Finally, radiation resulted in a near 50% reduction in endothelial cell outgrowth from 
aortas, a marker of endothelium damage. While the treatments could not fully prevent the 
endothelium damage, lipid vesicles showed more outgrowth than the radiated saline. 
Objective:  
The goal of this work was to assess the curcumin nanoparticles’ effectiveness at reducing 
the 56Fe radiation induced cardiovascular pathologies. We hypothesized that mice treated with 
the curcumin nanoparticles will exhibit reduced ROS in the cardiovascular tissue, reduced tissue 
remodeling, and reduced endothelial cell damage in response to radiation exposure. To achieve 
this, two aims were addressed.  
Aim 1: Characterize the effect of 56Fe radiation on mouse cardiovascular tissue (heart and aorta).  
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Aim 2: Examine the effectiveness of three independent curcumin drug delivery mechanisms at 
reducing mouse cardiovascular tissue damage caused by 56Fe radiation. 
II. METHODS 
Mouse Model:  
The overall experimental design involved a post-test only design on 54 wild type mice 
(C57BL/6J 6 month old males) because the assessment of the cardiovascular system following 
radiation exposure required sacrifice of the mice. There were a total of 6 groups of mice: 1. 
Injected with saline but not irradiated (NR Saline), 2. Injected with saline and irradiated (Rad 
Saline), 3. Injected with curcumin without a drug delivery vehicle and irradiated (CCM), 4. 
Injected with lipid drug delivery vehicle with CCM and irradiated (Lipids), 5. Injected with 
albumin drug delivery vehicle with CCM and irradiated (Alb/CCM), and 6. Injected with 
chitosan drug delivery vehicle with CCM and irradiated (Chitocurc). The number of mice given 
each treatment is listed in Table 1 below. The amounts of curcumin delivered with each drug 
delivery vehicle and their release times are listed below in Table 2. All studies carried out 










TABLE 1: Table of the different test groups of mice. 
Contents Injected Radiation (yes/no) Treatment 
Abbreviation 
Number of mice 
Saline No NR Sal 9 
Saline  Yes Rad Sal 10 
Chitosan with 
curcumin 
Yes Chitocurc 9 
Lipids with curcumin Yes Lipids 10 
Albumin with 
curcumin 
Yes Alb/CCM 10 
Curcumin Yes CCM 6 
 
TABLE 2: Curcumin release from delivery vehicles 
Delivery Vehicle CCM Release in μg/kg 100% release time in vitro 
Lipids  121 15 min 
Alb/CCM  252 60-90 min 
Chitocurc  6900 19 days 
CCM 273 Immediate 
 
Methods and Analyses:  
Radiation:  
Mice (6 months old and of type C57BL/6J) are common animals used in high energy 
radiation models [40-42].  Each of the mice was injected in the tail vein with either one of the 
drug delivery mechanisms or saline. All groups except for the non-radiated saline (NR Sal) 
treatment group were exposed to 20 cGy of 1000 MeV/n 56Fe at 20 cGy/min at Brookhaven 
National Labs. Two weeks (14 days ±2 days) following radiation the mice were sacrificed. The 
two week time point was selected to allow for transport back to UofL and minimize any possible 
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effects from transportation. For this particular project, the hearts and aortas were harvested to 
examine the effects of the radiation and the drug delivery vehicles.  
Tissue Harvesting:  
The hearts and aortas were kept together when dissected from the mice, and immediately 
placed in endothelial growth media without serum (medium 200). The connective tissue was 
carefully removed from the aorta and heart under a dissecting scope. Briefly the heart and aorta 
were pinned to a layer of PDMS in a petri dish and covered in endothelial growth media for the 
cleaning process. A set of Vannas spring scissors was used to gently pull the connective tissue 
away without damaging the heart or aorta. Then the heart and aorta were cut so that they were no 
longer connected to each other. Each aorta was flushed with endothelial growth media to remove 
blood. Using a scalpel, the heart was initially cut into three cross-sections containing: the atria, 
the ventricles, and the apical ventricles.  
Aortic Outgrowth Assay:  
The aortic outgrowth assay was adapted from the method used by K. Soucy et al [40].  A 
one centimeter cross-section was cut from the center of each aorta with a scalpel for the aortic 
outgrowth assay. This one centimeter section was cut into four equal pieces with a scalpel, three 
of which were used in aortic outgrowth assay, so that each aorta could be tested in triplicate. The 
number of mice used from each treatment group are listed in Table 3. The assay was a Matrigel 
matrix endothelial cell outgrowth assay utilizing Matrigel (BD Biosciences) diluted 1:1 with 
endothelial cell outgrowth assay with serum (Medium 200 phenol red free). The diluted Matrigel 
solution (150 µL) was added to each well of a sterile 48-well cell culture plate with care to 
minimize bubbles and incubated at 37°C for at least 30 minutes to cure. One ring of aorta was 
gently placed with tweezers in the center of each well with the lumen of the aorta oriented 
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horizontally. Then the aortas were covered with 100 μL of diluted Matrigel to fix the aorta in 
place. The samples were incubated for 4 days and then the cell outgrowth from each end of the 
aorta was imaged using the 4x objective on a light microscope (Nikon Eclipse TE2000-U, 
Japan). The image was taken using the focus plane that displayed the greatest number of cellular 
outgrowth.  
TABLE 3: Number of mice in each group for aortic outgrowth assay. 
Treatment Number of mice 
NR Saline 5 






NIH ImageJ software was used to quantify aortic outgrowth. Only one image per aorta 
slice was quantified, resulting in a total of three images per mouse, one from each well. The end 
of the aorta with the most cell growth from each slice was selected for imaging and 
quantification. Each image was opened in ImageJ twice so that one was used for quantification 
and the other used for comparison during the analysis. A custom macro was run to convert the 
image to 8-bit and set the scale (pixel to micron ratio) as well as to run the functions 
“background correction” and “unsharp mask” in ImageJ. The resultant image is shown in Figure 
1B. Then the image was given a threshold using the Threshold command as shown in Figure 1C 
to filter out any selections that are not outgrowth. The automatic threshold was accepted unless it 
resulted in non-outgrowth selections, in which case the threshold was adjusted until only cell 
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outgrowth was selected. Then the figure was converted to binary (Figure 1C below) in order to 
make a monochromatic image. A polygon was then drawn around the outgrowth using the 
Freehand Selection tool to separate the outgrowth from the aorta (Figure 1E).  The measurement 
of the outgrowth within the polygon area was taken, allowing for quantification of the total area 
of the outgrowth from each aorta.  
 
 
FIGURE 1: ImageJ Analysis of Aortic Outgrowth. All images with scale bar of 50 μm. A. 
Original image of the aorta. B. Outgrowth quantification macro applied. C. Thresholded image. 
D. Image converted to Binary. E. Freehand selection of the outgrowth area. 
 
Immunostaining:  
Immunostaining was done on the outgrowth assay aortas to ensure that the cells 
quantified were endothelial cells. Immediately after the light images described above were 
captured, the samples were fixed with 4% formaldehyde for 1 hour. The samples were stored in 
1X PBS in the refrigerator.  
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Isolectin-B4- AF488 (Invitrogen) is an antibody that stains endothelial cells specifically. 
Isolectin-B4- AF488 (IB4) was diluted to 1:1000 in 0.1 % bovine serum albumin (BSA) and 
added to the samples, which were incubated for 2 hours at 37C. Samples were washed four times 
with PBS at room temperature for 10 minutes each.  DAPI (SIGMA-Aldrich) at 30μM in 0.1% 
BSA was used to stain the nuclei in the sample for 15 minutes at 37°C. Samples were washed 6 
times with PBS and then imaged with fresh PBS. 
The immunostained aortas were visualized on an epifluorescent microscope with a 
fluorescence illumination system (X-Cite 120 from EXCO). A white light image was also taken 
for the purpose of confirming location. The aortas were captured at 20x magnification using NIS 
Elements Acquisition program. Three images were taken for each side of the aorta, each on a 
different focal plane since in Matrigel the cells were in a three dimensional matrix and so did not 
all grow in one plane. The violet filter with an excitation wavelength range between 379 and 420 
on the fluorescent microscope was used to locate viable nuclei that had been stained with DAPI. 
Then the white light filter was used for an overall view before the blue light filter with an 
excitation wavelength range between 420 and 495 was used to identify the endothelial cells 
stained with IB4. The IB4, white light, and DAPI images were taken without changing the focus 
so that the images could be merged.  
ROS Assay:  
The remaining aorta pieces from the mice shown in Table 4 below were weighed and 
solubilized in RIPA buffer(Cayman Chemicals) with 10 µg/ml leupeptin and 1 mM EDTA and 
then homogenized with an electric tissue homogenizer (Fisher Scientific, USA)  on ice. After 
homogenization, the samples were be centrifuged at 1600 x g at 4°C for 10 minutes, and the 
supernatants were be collected and frozen at -80°C to be saved for the ROS assay (TBARS 
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Assay Kit (Cayman Chemical)). The amount of ROS in the aortas was quantified to assess the 
cardiovascular damage from the radiation. For the assay 1 g thiobarbituric acid, 10 mL acetic 
acid in 40 mL water, 10 mL of 3.5 M sodium hydroxide in 40 mL water, 1 mL of 500 μM 
malondialdehyde, and 10 mL of 10% trichloroacetic acid was prepared following manufacturer’s 
instructions. To prepare the color reagent, 106 mg of TBA, 10 mL of the diluted acetic acid, and 
10 mL of the diluted sodium hydroxide were mixed together. For calorimetric measurement, the 
standards were created according to the TBARS assay kit protocol of standards of MDA of 
concentrations from 0-50 μM. After reagent preparation, 100 μL of a sample was added to 100 
μL trichloroacetic acid and 800 μL of the color reagent. Each sample was vortexed and boiled for 
one hour. Next, the samples were placed in ice for 10 minutes to stop the reaction, then they 
were centrifuged. Triplicates of each sample were pipetted into wells (200 μL/ well) on the 96 
well plate. The absorbance was measured at 530-540 nm.  
TABLE 4: Number of mice in each group for ROS assay 
Treatment Number of mice 
NR Saline 3 






The fourth section of the one centimeter section of aorta was placed in 4% formaldehyde 
for 24 hours then switched to 70% ethanol to later be fixed in paraffin for histology. The 
ventricles were also placed in 4% formaldehyde for 24 hours then switched to 70% ethanol. 
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These aortas and ventricles samples were sent to the University of Louisville’s Pathology lab to 
be embedded in paraffin and cross-sectioned into 5μm slices. Four slides containing three tissue 
sections were made from each paraffin block, with the first being stained with hematoxylin and 
eosin (H and E stain) and the other three unstained 
Histology- H&E staining protocol:   
H and E is stain where hematoxylin stains nuclei while eosin stains eosinophilic 
structures like proteins. This was done for the aortas in Table 5 below. The stained slides were 
imaged using an EVOS XL Core Brightfield Microscope. 
TABLE 5: Number of mice in each group for H&E staining.  
Treatment Number of hearts Number of aortas 
NR Saline 5 2 
Rad Saline 4 3 
Chitocurc 4 4 
Lipids 3 3 
Alb/CCM 4 2 
CCM 4 3 
 
H and E Imaging:  
For the each cross-section of the ventricles, two images were taken at 4x to combine into 
a full view of the heart slice, two images were taken at 40x at different places on the left 
ventricle, and two images were taken at 40x at different places on the right ventricle. For the 
aortas, one image was taken at 10x for a full view and two images were taken at different 
locations on the aorta at 40x. The difference in magnification was due to the difference in tissue 
size between hearts and aortas. Since the hearts are much larger, a lower magnification was 
needed to take full images of the heart slices.  
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H and E analysis:  
Once these images were taken, they were analyzed in ImageJ. For the hearts, thickness of 
the left and right ventricle walls was quantified to examine for signs of fibrosis or cardiovascular 
disease. For this analysis, the image was first opened in ImageJ. Then the scale was set to change 
the distance from pixels to microns based on the magnification from the microscope. Once the 
image was opened, the Straight tool was used to draw lines across the left ventricle to measure 
the thickness. This was done at 5 points along each ventricle, and the mean thickness was noted 
for the left and right ventricles. The same thickness characterization and comparison was also 
done for the aortas.  
The second ImageJ quantification was a red/blue contrast quantification of the 40x 
ventricle images and the 40x aorta images. H and E stains nuclei blue and intracellular and 
extracellular protein red. There are a variety of shades of red for different proteins, and muscle in 
particular is stained dark red. Using thresholding techniques in Image J, the area of nuclei and 
muscle tissue can be quantified. To do this, first the image was opened in ImageJ. Then the scale 
was set using the Set Scale command to find the measurements in microns. Then, the Color 
Threshold command was used twice. The first time was to find the percent of the image that was 
muscle tissue. The Color Threshold command was used, and the scales were adjusted as shown 
in Figure 2B so that only the red hue area was selected as show in Figure 2C. Then the image 
was analyzed using the Analyze Particles command, choosing the create mask option in the drop 
down list. This mask is shown in Figure 2D. This process was repeated to select only the nuclei 
without the muscle layer as shown in Figure 2E. Again the image was analyzed and a mask 




FIGURE 2: H&E staining analysis with scale bars of 50μm. A: the original left ventricle image. 
B: muscle tissue selected in red. C: mask of muscle tissue. D: Nuclei selected in red. E: mask of 
nuclei. 
Histology – Masson’s Trichrome:  
Masson’s trichrome staining of the heart and aorta slices was also performed. This was 
done for one slide of each heart or aorta shown in Table 6 below. The staining for Masson’s 
trichrome was to differentiate between different extracellular matrix components, specifically 
collagen and elastin. The procedure for Masson’s trichrome staining was done with a kit from 
Sigma-Aldrich (HT15-1KT), by following manufacturer’s instructions. Weigerts Iron 
Hematoxylin solution was made from equal parts of hematoxylin component A and hematoxylin 
component B (Sigma). The Bouin’s solution as poured into a coplin jar that was then heated in 
the oven until it reached 56°C. The phosphotungstic/phosphomolybdic acid solution was made 
with one part phospotungstic, one part phosphomolybdic, and two parts reverse osmosis (RO) 
water. The paraffin as removed with two five minute washes in xylene, a three minute wash in 
100% ethanol, and three minute wash in 70% ethanol, and three minute wash in 50% ethanol, 
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and a three minute wash in distilled water. The slides are then placed in warmed Bouin’s solution 
for 15 minutes. Then the slides are placed in tap water for 5 minutes before being rinsed 
carefully under running RO water. Then the slides were dipped in Weigerts iron hematoxylin 
solution for 5 minutes before being rinsed in tap water for 5 minutes. Then the slides were placed 
in Biebrich scarlet-acid fucshin for five minutes followed by another RO water rinse. The slides 
were then stained with phosphotungstic/phosphomolybdic acid solution for five minutes 
followed by an aniline blue stain for five minutes. The slides were immediately placed in 1% 
acetic acid for 2 minutes then rinsed in RO water. The slides were then dehydrated with a one 
minute soak in 95% ethanol, two one-minute soaks in 100% ethanol, and two four-minute soaks 
in xylene. The slides are mounted with Permount and left to dry for 4 days before imaging. 
TABLE 6: Number of mice in each group for Masson’s Trichrome staining 
Treatment Number of hearts Number of aortas 
NR Saline 3 2 
Rad Saline 3 3 
Chitocurc 3 3 
Lipids 3 3 
Alb/CCM 3 2 
CCM 3 3 
  
Masson’s Trichrome Imaging 
The Masson’s Trichrome stained hearts and aortas were also imaged on the EVOS XL 
Core Brightfield Microscope. For the each slice of heart, two images were taken at 4x to 
combine into a full view of the heart slice, two images were taken at 40x at different places on 
the left ventricle, and two images were taken at 40x at different places on the right ventricle. For 
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the aortas, one image was taken at 10x for a full view and two images were taken at different 
locations on the aorta at 40x. 
Masson’s Trichrome Analysis 
These images were also analyzed in ImageJ. The scale was set using the Set Scale 
command to find the measurements in microns. Then, the Color Threshold command was used 
which has 3 adjustable options: Hue (a specific color tone), Saturation (how vivid a color is), and 
Brightness (relative lightness or darkness). Each of these options is from 0-255, allowing for 256 
possible values of color hue, saturation, and brightness with 8 bits per pixel. The first time, for 
the selection of the entire aorta, the Hue slider covered the entire range of options from 0-255. 
Then Saturation was adjusted to eliminate background noise by not selecting the lowest 
saturation levels. The brightness was selected as 100-255, since this was the point at which all 
parts of the aorta were selected without any pieces mistaken for background. The image was then 
converted to binary and measured as shown in Figure 3B. Next, the original reopened and the 
color Threshold was used again with the Hue slider adjusted so it only selected the red range, 
generally between 215 or 225 to 255. This excluded the adventitia and nuclei from 
quantification. The saturation and brightness were the same as the previous image. The binary 
image is shown in Figure 3C. The third step was to find the elastin in the media layer. For this, 
the image was zoomed in on so that the lines of elastin could be seen. The hue slider was moved 
to exclude the lower levels of red, usually selecting around 248 or 250-255. The image was then 
converted to binary and measured as shown in Figure 3D. The next selection was of smooth 
muscle cells. The bottom of the media layer threshold from the previous measurement in 3C 
served as the bottom threshold for the hue. The lower number of the elastin threshold in 3D 
minus one was the upper threshold for the hue threshold. These measurements would result in a 
hue range similar to 215-248. The brightness was made to include the full range of brightness.  
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This was then converted to binary and measured as shown in Figure 3E, representing smooth 
muscle in the media layer. The next selection was of the adventitia layer. The low threshold for 
the hue was adjusted until as much of the adventitia as selected as possible without other layers 
being selected, often at around 90. The high threshold for the adventitia was defined as the low 
threshold from the media layer (2C) minus one. This image was converted to binary and 
measured, representing adventitia area (Figure 3F). The final selection was of the collagen in the 
adventitia. The lower hue threshold was measured by zooming in to the image and selecting until 
as much of the collagen was selected as possible without other parts of the aorta being selected, 
similar to the method of selecting elastin. The high threshold of the adventitia starts at the low 
threshold for the media layer minus one, but may need to be reduced further to eliminate some 
pink or purple area in the adventitia. The collagen layer in the adventitia was also converted to 
binary and measured as shown in Figure 3G. The thickness was calculated for the total aorta 




   
FIGURE 3: Masson’s Trichrome Imaging with scale bar of 200μm. A. Original image of an 
aorta. B: Selection of entire aorta. C: Selection of aorta without the nuclei. D. Selection of elastin 
in muscle layer. E. Selection of smooth muscle cells. F. Adventitia. G. Collagen in adventitia 
layer. 
 The same method of analysis used for the aortas was used for the hearts. The entire heart 
tissue excluding the nuclei was selected as described for the aortas. The amount of collagen (blue 






Histology- Immunofluorescent Staining:  
The immunofluorescence staining also started with rehydrating the tissue on the slides 
(one slide per heart or aorta as show in Table 7 below), with two five-minute rinses each in 
xylene, 100% ethanol, 95% ethanol, 90% ethanol, 85% ethanol, 80% ethanol, and 70% ethanol. 
All of the rinses were done in coplin jars. These rinses were followed by a five minute rinse in 
DI water and then a five minute rinse in phosphate buffered saline (PBS). The tissue was 
permeabilized with 1% triton in 1M glycine for 30 minutes at room temperature in a humidity 
chamber before being rinsed three times in PBS for five minutes each. Before the 
permeabilization step, an aquapen was used to draw a circle around the tissue slices to hold the 
triton mixture in place above the tissue. The 5% BSA was added to the slide, which was placed 
in a humidity chamber. After three more rinses in PBS, the primary antibody solution was added 
with an overnight incubation at 4°C in the humidity chamber. The primary antibody solution was 
a 1:50 mixture of polyclonal rabbit anti-TGF-β (sc-146, Santa Cruz Biotechnology) and PBS. 
After this step, everything was done in the dark since the secondary antibody and DAPI are 
photo-sensitive. Then the sample was rinsed 3 times in PBS, and the secondary antibody solution 
was added to incubate for 90 minutes at room temperature in the humidity chamber. The 
secondary antibody was Alexa Fluor 555 donkey anti-rabbit diluted a 1:15 solution with PBS. 
There were then another three rinses then five minutes of staining with 300 μM DAPI diluted 
1:10 in PBS to show nuclei. Finally samples were rinsed 3 times with PBS and three times with 
water before the 1 drop of FluorSave was added as mounting solution and covered with a 
coverslip.  
Immunofluorescent Imaging 
A confocal microscope, the Nikon Eclipse Ti, was used for the imaging (Table 7). The 
images were captured and analyzed using NIS Elements Analysis. The capture was done at 60x, 
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and 3 images were taken per slice of aorta, making 6 images per slide since there were two slices 
per slide. The settings for all images captured was pinhole size at 1.0, frame rate was 1/8, size at 
1024, DAPI laser power at 1.25, TxRed laser power at 1.5, and light HV at 125. When imaging 
the hearts, the TxRed laser power was 2.5 rather than the 1.5 used for the aortas because the 1.5 
power did not show the fluorescence well in the hearts while 2.5 did. 
TABLE 7: Number of mice in each group for Immunofluorescent staining 
Treatment Number of hearts Number of aortas 
NR Saline 3 2 
Rad Saline 3 2 
Chitocurc 3 3 
Lipids 3 2 
Alb/CCM 2 2 
CCM 3 2 
 
Immunofluorescent Analysis 
An image was opened in NIS Elements Analysis, the TD (white light) tab was chosen, 
and the white light was brightened as shown in Figure 4B. Then, the Draw Polygon tool from the 
Annotations and Measurements tab was used to separate the adventitia and smooth muscle of the 
aorta (in the case of imaging aortas) as shown in Figure 4C. Once this was done, the image was 
changed over to the TxRed tab, which contains the image of TGF-β1 fluorescence.  A 60 pixel 
by 120 pixel rectangle was created. Four of these rectangles were in the adventitia layer, 4 in the 
medial layer, and 4 not in the aorta measuring the background intensity. The mean of these 4 
TxRed sum intensity measurements was taken for each section. For the ventricles, rather than 
four rectangles, a single 500 pixel x 500 pixel square was used for intensity measurements since 
the ventricles were not split into specific layers. To measure background noise, a 50 pixel x 50 
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pixel square was placed in an area without tissue.  The sum intensity of this measurement was 
used as the background signal and multiplied by 100 before subtracting out of all tissue 
measurements. The multiplication of the sum intensity from the background measurement by 
100 was to have equivalent box sizes to the tissue measurement boxes for proper background 
subtraction. 
   
FIGURE 4: Quantification of TGF-β1, shown in red, in immunofluorescent images with a scale 
bar of 50 μm. A: the stained aorta with all channels showing. B: the lightening of the white light 
image using the LUT panel, using the draw polygon tool of the annotations and measurements 
tab to divide the adventitia and smooth muscle layers. C. All channels shown and the calculation 






The same statistical analysis techniques were used for the aortic outgrowth, ROS assays, 
and all histological tests. To fulfill aim 1, “Characterize the effect of 56Fe on mouse 
cardiovascular tissue (heart and aorta)”, the NR Sal and Rad Sal groups were compared using a 
t test with an alpha of 0.05 to indicate significance. To fulfill aim 2 “Examine the effectiveness of 
three independent curcumin drug delivery mechanisms at reducing mouse cardiovascular tissue 
damage caused by 56Fe”, all groups that received radiation were compared using an ANOVA 
with an alpha value of 0.05 to indicate significance, after which Tukey tests were run for the post 
test.  
The n values used for each assay are in the relevant methods sections, as are 
representative images for each treatment group. For each test, there is a graph in the relevant 
methods section containing the averages for each treatment group as well as the standard 
deviations.  
III. RESULTS AND DISCUSSION 
Aortas: 
Aortic Outgrowth Assay:   
Aortic outgrowth was measured by quantifying the area of the new cell growth from the 
sliced aorta using ImageJ. The cell outgrowth represents the aorta’s ability to repair itself, which 
is hindered by radiation, as shown by compromised angiogenesis in a study by Soucy et al [40]. 
Ionizing radiation has also been shown to cause endothelial cell apoptosis[43], further hindering 
the growth of the aorta. The results of this study did not show a significant difference between 
Rad Sal and NR Sal groups, with a p value of 0.530 in the t-test. The treatment groups did not 
show a significant difference in outgrowth compared to Rad Sal either (p = 0.160 for the 
ANOVA). The resultant graph is shown below in Figure 5, and representative images for each 
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treatment group are shown below in Figure 6. The aortic outgrowth trends in this study were 
replicated by a separate blinded analysis of the images. While there are no statistically significant 
differences between the groups, there are trends showing the Alb/CCM treatment inspired the 
highest outgrowth, with a 35% increase in outgrowth area compared to Rad Sal. This increase in 
outgrowth could be from enhanced effectiveness of the antioxidant curcumin, which scavenges 
ROS that causes decreased aortic outgrowth.  However in other studies curcumin has been 
shown to decrease angiogenesis. The effects of curcumin on cell proliferation which is important 
for angiogenesis is variable throughout literature. Curcumin’s effect on angiogenesis is possibly 
dependent on dosage and tissue. Curcumin has been found to hasten wound healing, increasing 
proliferation and collagen synthesis at a wound site [44, 45]. In a rat experiment with topically 
applied curcumin for wound healing, experimental rats received 200 μl of the curcumin at a 
concentration of 40-mg/kg-body weight, and in that experiment curcumin led to proliferation 
[44]. In other applications, such as cancer prevention, curcumin has been shown to limit 
proliferation and angiogenesis [46]. In the Arbiser et. al study, concentrations of curcumin of 
0.5- 10 μM were added to primary endothelial cells in the eye, with curcumin inhibiting 
endothelial growth, the largest cell decrease happening at 10 μM. Given the different doses of 
curcumin released for each nanoparticle in our study (listed in Table 2), decreased aortic 
outgrowth could be from decreased proliferation induced by curcumin in the Lipids, Chitocurc, 
and CCM treatments.  
Compared to the study by Soucy et al. [40], the results described here show less effect of 
radiation Soucy et al used gamma radiation at doses of 0.5 Gy and above rather than 20 cGy of 
56Fe radiation. In the Soucy et al. study, the higher doses of radiation reduced aortic outgrowth, 
and the lowest does of 0.5 Gy dose had a small significant effect (reduction of outgrowth from 
26 
 
1.00 ± 0.22 at 0 Gy to 0.897 ± 0.022 at 0.5 Gy, p<0.05).  Whereas in this study, the radiation 
dose did not show a significant effect, with a slight increase in outgrowth due to radiation. This 
unexpected result could be due to the lower dose of radiation and different type of radiation 
exposure used here. Since the variation in the data was higher in this study, this could be another 
reason why the radiation effects did not prove to be significant as well as explaining why there 
was a reverse of the expected trend in the Rad Sal and NR Sal groups. 
 
 































FIGURE 6: Representative images for Aortic Outgrowth Assay - A: NR Sal, B: Rad Sal. C: 
Chitocurc. D: Lipids. E: Alb/CCM. F: CCM 
Immunostaining:  
Immunostaining was performed on several of the aortic outgrowth assay wells with 
higher levels of outgrowth to ensure that the cells growing from the cut ends of the aorta in the 
aortic outgrowth assay were in fact endothelial cells. It has been observed in a study by Soucy et 
al. that in aortic outgrowth, the majority of the outgrowth comes from the endothelium [40]. 
Endothelial cells are the ones that demonstrate the growth and repair of the vasculature. In Figure 
7 below, the white light demonstrates the full image of the outgrowth, the blue image shows the 
DAPI stained nuclei, and green images show the IB4 stained endothelial cells. Although the 
staining is very dim, the majority of outgrowth was stained lightly as endothelial cells, rather 




FIGURE 7: IB4 immunostained aorta – A: Brightfield image. B: violet filter/DAPI image. C: 
blue filter/FITC image. Due to low intensity in the IB4 stained image (image C), additional post 
processing was done to enhance visualization. Background subtraction was done in ImageJ using 
the max greyscale value found in the area in the bottom right corner. Then an unsharp mask was 
applied with a radius (sigma) of 80 pixels and mask weight (0.1-0.9) of 0.65. 
ROS Assay:  
The ROS assay was performed to assess the amount of ROS in the aortas. These 
measurements examined the ROS levels in aortas 14 days after radiation. The reason for 
examining the amount of chronic ROS was because the treatments contained curcumin, an 
antioxidant, which can reduce ROS levels. The results are shown in Figure 8 below. When the 
results were run in Minitab, there were no significant differences shown between the NR Sal and 
Rad Sal treatment groups, with a p value of 0.772. This data suggests the radiation did not 
increase chronic ROS in aortas. The ANOVA run for the treatment groups excluding NR Sal had 
a p value of 0.719, showing a lack of effect from the CCM treatments. All of the groups except 
Chitocurc had averages very similar to each other, with ROS in mouse tissue treated with 
Chitocurc demonstrating a 29% decrease in ROS compared to Rad Sal. One possible explanation 
for the reduced ROS in Chitocurc treated tissues was that Chitocurc released CCM over the 
course of 19 days in this treatment, so the antioxidant release could still be occurring at the time 
of. These results differ from a separate ROS assay done on the bone marrow of the same mice by 
a collaborator in which there was no significant difference between the NR Sal and Rad Sal, but 
all the drug treatments did lower the ROS levels. The differences in results might exist due to the 
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fact that the collaborator used fresh tissue in their study while this study used frozen tissue to 
assess the ROS in the aortas. In addition, the sensitivity to radiation and ROS may vary from 
tissue to tissue.  However, both assays of 2 different tissues found that ROS levels were not 
elevated 14 days after the radiation treatment in saline treated mice.   
 
 
FIGURE 8: Graph of the ROS assay. 
Histology:  
Histology – H&E 
In order to see if the radiation and treatments effected the heart and aorta tissue 
organization, hematoxylin and eosin staining was performed. Hematoxylin and Eosin staining is 
a global stain of nuclei in which stains nuclei blue and smooth muscle red. The amount of 
smooth muscle per nuclei was calculated using ImageJ to examine changes in cell growth. The 
calculations were done measuring the amount of smooth muscle per nuclei with the assumption 
that a smaller area of smooth muscle per nuclei would indicate cell multiplication. The 
representative images are in Figure 9 below, and the graph of the average amount of smooth 





















NR Sal and Rad Sal groups, with a t test p value of 0.760. There was also no difference between 
any of the drug treatment groups and the Rad Sal group, with a p value 0.454. The trends showed 
Rad Sal only had a 6% decrease in smooth muscle per nuclei compared to NR Sal, while the 
CCM group had a 21% increase in smooth muscle per nuclei compared to Rad Sal, suggesting 
ventricular smooth muscle cell hypertrophy. Chitocurc was very close in value to NR Sal with an 
8% increase in smooth muscle per nuclei compared to Rad Sal, while Lipids actually showed a 
12% decrease in smooth muscle per nuclei compared to Rad Sal, suggesting an increase in 
ventricular smooth muscle cell proliferation.  
 
FIGURE 9: Representative Images for the amount of smooth muscle per nuclei in the aortas. A: 






FIGURE 10: Graph of the averages and standard deviations for the smooth muscle per nuclei 
measured in μm2 in the H&E stained aortas.  
Histology – Wall Thickness: 
The wall thicknesses of the aortas were compared between treatment groups to test if the 
radiation caused thickening of the aorta walls. Thickening of the aorta walls would lead to 
decreased flexibility of the vasculature and so increased blood pressure and cardiovascular 
damage. Thickening of other arteries such as the carotid arteries has been shown as a result of 
56Fe radiation, shown in the thickening of the intima as show by immunohistochemical and 
immunofluorescence staining at 13 weeks after radiation[47]. Similar thickening was expected of 
the aorta. The representative images are shown below in Figure 11 while the graph of the 
averages and standard deviations for each group is in Figure 12. There were no significant 
differences between NR Sal and Rad Sal, with a p value of 0.240 in the t test, but the Rad Sal 
group had a 39% increase in wall thickness compared to the NR Sal group. The different drug 
treatment groups did not have significant differences either, with a p value of 0.501 in the 
ANOVA. The Alb/CCM and Lipids treatments lead to thinner aortas than the Rad Sal group with 























Smooth muscle area per nuclei for Aortas
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some protective ability from vessel thickening from the curcumin delivered by Alb/CCM and 
Lipids. There are also lower standard deviations for the NR Sal, Chitocurc, and Alb/CCM 
groups, with standard deviations of 0.35 (0.6%), 5.4 (7.1%), and 4.9 (9.7%) respectively 
compared to the standard deviation of 24 (29%) for the Rad Sal group. This could imply that the 
radiation effects were highly varied between mice and be a consequence of a low n value.  
 
FIGURE 11: Representative images for the wall thickness of the aorta. A: NR Sal, B: Rad Sal. C: 





FIGURE 12: Graph of the wall thicknesses of the H&E stained aortas.  
 
Histology – Masson’s Trichrome: 
Masson’s Trichrome is a three color stain that stains muscle tissue dark pink/red, ECM light 
blue, and nuclei dark blue. This stain allows the separate layers of the aorta to be differentiated 
into the media layer and adventitia layer. The thicknesses of the adventitia layer of the Masson’s 
trichrome stained aortas was measured to determine whether a certain layer was thickening 
rather than the entire aorta. For the adventitia thickness alone, there was no significant difference 
between NR Sal and Rad Sal as a result of radiation with a p value of 0.498. Nor was there a 
difference between Rad Sal and the treatment groups, with a p value of 0.788. The adventitia 
layer thickness was also measured as a percentage of the total aorta thickness. There was no 
significant difference in the % of the total aorta thickness that was adventitia between the NR Sal 
and Rad Sal groups, with a p value of 0.736. Nor was there a difference in the percentage of the 
aorta that was adventitia as a result of the treatments, with a p value of 0.819 between the 
treatment groups and Rad Sal. Below in Figure 13 the thicknesses of each layer of the aorta are 

























All treatment groups had higher percentages of adventitia compared to NR Sal. The 
representative images are shown in Figure 15 below, with the strip of blue on each aorta being 
the adventitia layer.  
 After finding the amount of adventitia, the amount of the adventitia that is the ECM 
protein collagen was measured. In this case, it was area rather than thickness that was found in 
ImageJ. The collagen is the specific ECM protein that is linked to fibrosis, so it serves as a 
signifier of cardiovascular damage. The radiation did not show a significant effect on the percent 
collagen within the aorta compared to NR Saline, with a p value of 0.777 in the t tests, none of 
the treatments were significantly different than the Rad Saline with a p value of 0.840 in the 
ANOVA. There were very high standard deviations as shown in Figure 16, with standard 
deviations as high as 92% of the % collagen. This standard deviation was partially due to 
differences between mice and partially due to the method of analysis which required identifying 
collagen from the rest of the adventitia by eye. The Rad Sal group has a higher average level of 
collagen than the NR Sal group, with a 23% increase in collagen area, though the standard 





FIGURE 13: Graph of the wall thicknesses of each layer of the aorta stained with Masson’s 
trichrome.  
 
























Layer Wall Thicknesses - Masson Trichrome Aortas





























FIGURE 15: Representative images of wall thicknesses of aortas stained with Masson’s 
trichrome. A: NR Sal, B: Rad Sal. C: Chitocurc. D: Lipids. E: Alb/CCM. F: CCM 
 
FIGURE 16: Graph of the % of the total aorta area that is adventitia and the amount of the total 
aorta area that is collagen. 
Histology – Immunostaining:  
TGF-β1 is a signaling molecule highly expressed in fibrosis. The images for the aortas in which 
TGF-β1 is stained for are shown below in Figure 17, and the averages of the intensity of the 
























deviations are very high between groups, resulting data difficult to draw conclusions from. There 
is no significant effect of radiation according to the t test between NR Sal and Rad Sal with a p 
value of 0.600. There was also no significant effect of the drug treatments according to the 
ANOVA with the p value of 0.832. There are trends indicating that the NR Sal and Lipids groups 
have the lowest amount of TGF-β1 compared to Chitocurc or Rad Sal, however, the standard 
deviation is too high to be certain. The standard deviations are lower in the case or NR Sal and 
Lipids compared to those of the Rad Sal and Chitocurc treatments, indicating that the increase in 
TGF-β1 expression is variable between groups and within groups. 
 
FIGURE 17: Representative images for the immunostained histology aorta slides. A: NR Sal, B: 
Rad Sal. C: Chitocurc. D: Lipids. E: Alb/CCM. F: CCM 
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FIGURE 18: Averages and standard deviations for immunostained aortas for both the adventitia 
and smooth muscle.  
Ventricles: 
Histology: 
Histology – H&E 
 In order to see if the radiation and treatments effected the heart, hematoxylin and eosin 
staining was performed. Hematoxylin and Eosin staining is a global stain of nuclei in which 
stains nuclei blue and cardiac muscle red. The representative images are in Figure 19 and 20 for 
the right and left ventricles respectively, and the graph of the average amount of cardiac muscle 
area per nuclei is in Figure 21 below. The radiation had a significant effect on the right ventricle 
area per nuclei, with a p value of 0.041 in the t test. The drug treatments did not have a 
significant impact on area per nuclei, with a p value of 0.997 from the ANOVA. For the right 
ventricle, the radiation caused a 16% decrease in cardiac muscle area per nuclei, comparing Rad 
Sal to NR Sal. None of the antioxidant treatments altered this effect, with the largest change 


























There was no significant effect of radiation in the amount of cardiac muscle per nuclei in 
the left ventricle, with a p value of 0.562 in the t test. There was not a significant effect of the 
drugs either, with a p value of 0.347 in the ANOVA. There was only a 6% decrease in cardiac 
muscle area per nuclei, and the only group that increased the cardiac muscle area per nuclei was 
CCM, with an increase of 13% compared to Rad Sal. 
 
 
FIGURE 19: Representative Images for the amount of cardiac muscle per nuclei in the right 
ventricle. For each image, the original, smooth muscle, and nuclei are shown. A: NR Sal, B: Rad 




FIGURE 20: Representative Images for the amount of cardiac muscle per nuclei in the left 
ventricle. For each image, the original, smooth muscle, and nuclei are shown. A: NR Sal, B: Rad 
Sal. C: Chitocurc. D: Lipids. E: Alb/CCM. F: CCM 
 
FIGURE 21: Graphs of the averages and standard deviations for the cardiac muscle in μm per 
nuclei in the H&E stained right and left ventricles 
 
Histology – Wall Thickness 
 The wall thicknesses of the ventricles were compared between treatment groups to test if 
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could lead to similar effects as the stiffening of arteries, with decreased flexibility and increased 
blood pressure. This would imply cardiac hypertrophy which indicates increased effort for the 
heart to pump. The representative images of the right and left ventricle are shown below in 
Figure 22 and 23, while the graph of the averages and standard deviations for each group is in 
Figure 24.  
For the right ventricle, there is a significant difference between the NR Sal and Rad Sal 
showing an effect of radiation, with a p value of 0.026 in the t test. The Rad Sal shows a 15% 
increase in wall thickness compared to the NR Sal.  There is not a significant effect of the 
antioxidant treatments in comparison to Rad Sal, with a p value of 0.497. All antioxidant 
treatments showed a trend of a slight decrease in wall thickness, with Chitocurc, Lipids, 
Alb/CCM, and CCM showing a 14%, 13%, 8%, and 12% decrease respectively compared to Rad 
Sal.  
For the left ventricle, there is not a significant difference between NR Sal and Rad Sal, 
with a p value of 0.343, but there is an effect of the antioxidant treatments since the ANOVA has 
a p value < 0.001. In this case, rather than a thickening as a result of radiation, there seems to be 
a thinning, with Rad Sal decreasing in wall thickness by 22% compared to NR Sal. The 
Alb/CCM and CCM antioxidant treatments seem to prevent this ventricular thinning, with an 
increase of 55% and 61% increase in wall thickness respectively compared to Rad Sal. The 
Tukey test used as a post test for the ANOVA resulted in an adjusted p value of 0.018 between 




FIGURE 22: Representative images for the wall thickness of the right ventricle. A: NR Sal, B: 
Rad Sal. C: Chitocurc. D: Lipids. E: Alb/CCM. F: CCM 
 
FIGURE 23: Representative images for the wall thickness of the left ventricle. A: NR Sal, B: 




FIGURE 24: Graph of the wall thicknesses of the right and left ventricle as measured from the 
H&E stained slides.  
 
Histology – Masson’s Trichrome 
 Masson’s Trichrome is a three color stain that stains smooth muscle dark pink/red, ECM 
light blue, and nuclei dark blue. In this case this would allow the amount of collagen to be 
quantified in ImageJ, since collagen is a major marker of fibrosis. In this case, however, the 
collagen made up less than 1% of the total area in each ventricle as can be seen in Figure 25 
below which shows representative images of the left ventricle. The collagen would show up blue, 
but little if any blue can be seen in the images below. The graph indicating the levels of collagen 
in the left and right ventricles is in Figure 26 below. Since the highest level of collagen was still 
below 1%, it can be concluded that increased collagen levels associated with fibrosis was not 
observed in this study. These results contrast with those of a study by Zeng et al. [48] which 
studied the effects of radiation induced damage of the myocardium with  gamma radiation. In 
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Gy radiation and as much as a 5 fold increase in collagen compared to the non-radiated mice. In 
the Zeng et al. study, however, the mice were given much larger doses of radiation compared to 
the study here as well as sacrificing the mice after 4 months rather than 2 weeks.  
 
FIGURE 25: Representative images of the collagen amount found in the left ventricle of the 
hearts. A: NR Sal, B: Rad Sal. C: Chitocurc. D: Lipids. E: Alb/CCM. F: CCM 
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Histology – Immunostaining:  
The ventricles were also tested for TGF-β1 via immunohistology since TGF-β1 is linked 
to collagen deposition and cardiac fibrosis. The graph of the averages and standard deviations is 
below in Figure 29. The representative images are below in Figures 27 and 28. There was no 
significant effect of the radiation in the right or left ventricles comparing NR Sal and Rad Sal 
treatments, with t tests showing p values of 0.920 and 0.440 respectively. There were also no 
significant effects of the curcumin delivery vehicles in the right or left ventricles, as shown by 
ANOVAs with p values of 0.620 and 0.894 respectively.  While there were no significant 
differences, there were trends. For the right ventricle, there was almost no change based on the 
radiation, with a 4% decrease in Rad Sal compared to NR Sal. The Chitocurc and CCM groups 
featured increases of 40% and 41% increases in TGF-β1 compared to Rad Sal. The Alb/CCM 
treatment showed a 35% decrease in TGF-β1 compared to Rad Sal. For the left ventricle, there 
was a 55% increase in TGF-β1 in the Rad Sal treatment compared to NR Sal. There is a 37% 
decrease in TGF-β1 expression in the Alb/CCM group compared to Rad Sal. These trends could 
show that the Alb/CCM treatment does the most to reduce the expression of TGF-β1, while 
Chitocurc and CCM may increase the expression of TGF-β1, at least in the right ventricle. A 
study by Liu et al. using 20 Gy gamma radiation noted something more similar to the left 
ventricle results, with cardiac TGF-β1 mRNA being expressed more than in the non-radiated 
group with peaks at 2 and 12 weeks [49]. The Liu et al. study used a polymerase chain reaction 
to quantify the TGF-β1 as well as sacrificing at 2, 4, 8, 12, and 24 weeks rather than staining 
heart tissue to quantify and sacrifice after 2 weeks as was done in this study. Since Liu et al. 
quantified expression of mRNA rather that protein, it is possible that the peaks found by their 
mRNA studies at 2 weeks would not have translated into an increase in protein expression at that 
time point, similar to the observations found in this study.  
46 
 
       
FIGURE 27: Representative images for the TGF-β1 intensity of the right ventricle. A: NR Sal, 
B: Rad Sal. C: Chitocurc. D: Lipids. E: Alb/CCM. F: CCM. The representative images were all 





    
FIGURE 28: Representative images for the TGF-β1 intensity of the left ventricle. A: NR Sal, B: 
Rad Sal. C: Chitocurc. D: Lipids. E: Alb/CCM. F: CCM. The representative images were all 
given stronger contrast in post processing to make the TGF- β1 more visible. 
 
























IV. CONCLUSIONS, DISCUSSION, & RECOMMENDATIONS FOR FUTURE WORK 
Conclusions:  
Aortas: 
Aim 1 was to characterize the effects of heavy iron radiation on mouse cardiovascular 
tissue. To test this, the Rad Sal and NR Sal treatment groups were compared in all of the 
previously mentioned assays using t tests. The differences between the two were not significant 
in most of the tests, likely due to the low dose of radiation, type of radiation, and time point, but 
there were notable trends for each test. For the aortas, radiation seemed to increase in wall 
thickness compared to NR Sal, though the increase was variable. This thickening could result in 
stiffening of the vessel walls, which could lead to further cardiovascular problems or 
pathologies. Radiation exposure also increased the percent collagen in the aorta compared to NR 
Sal. This collagen increase would coincide with the vessel thickening, and with vessel stiffening 
documented by others. 
Aim 2 was to examine the effectiveness of three independent curcumin drug delivery 
mechanisms at reducing mouse cardiovascular tissue damage caused by heavy iron radiation. In 
the case of the aortas, there were no significant differences shown by ANOVAs done in Minitab, 
but there were trends. For the aortic outgrowth assay, the Alb/CCM treatment showed the highest 
level of aortic outgrowth in mice compared to the other treatments, with a noticeable increase 
compared to Rad Sal. This would imply that the Alb/CCM treatment was most effective in 
promoting angiogenesis. In the wall thickness measurements, the Alb/CCM and Lipids 
treatments led to large decreases in wall thickness compared to Rad Sal, implying that these 
treatments helped to prevent radiation-induced stiffening. These results show that while not 
statistically significant, there were noticeable effects of the antioxidant treatments to the aorta. 
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Each of the treatments had some effect counteracting the effects of radiation, with Alb/CCM 
showing the most positive countermeasure against the effects of radiation treatment.  
 
Ventricles: 
Aim 1 was to characterize the effects of heavy iron radiation on mouse cardiovascular 
tissue. To test this, the Rad Sal and NR Sal treatment groups were compared in all of the 
previously mentioned assays using t tests.  
Right Ventricle: For the cardiac muscle area per nuclei analysis, there was a statistical 
difference, with the radiation leading to a decrease in cardiac muscle area per nuclei comparing 
Rad Sal to NR Sal, indicating an increase in cells. For the wall thickness analysis, there was also 
a significant difference for the right ventricle, where the radiation appears to cause thickening of 
the right ventricle as signified by an increase in wall thickness in Rad Sal as compared to NR 
Sal. This thickening would lead to stiffening of the right ventricle, which may be an indication of 
cardiovascular disease. 
Left Ventricle: For the cardiac muscle area per nuclei analysis the radiation led to a 
decrease in cardiac muscle area per nuclei comparing Rad Sal to NR Sal. For the wall thickness 
analysis, there was a trend with a decrease in left ventricular wall thickness as a result of 
radiation compared to NR Sal. This was not an expected result and bears further study, possibly 
indicating a thinning of the left ventricle that can occur before hypertrophy as shown by Sutton 
and Sharpe [50]. There could also be some effect elsewhere in the heart or arteries downstream 
leading to this thinning. There was an increase in TGF-β1 left ventricle in the Rad Sal group 
compared to NR Sal. TGF-β1 stimulates growth and could be there in an attempt to repair the 
thinning of the left ventricle.  
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Aim 2 was to examine the effectiveness of three independent curcumin drug delivery 
mechanisms at reducing mouse cardiovascular tissue damage caused by heavy iron radiation. 
Right Ventricle: For the cardiac muscle area per nuclei analysis, there was not a statistical 
difference between any of the antioxidant treatment groups and Rad Sal, nor were there any 
noticeable trends, signifying that there was no protective effect observed for this metric. For the 
wall thickness analysis all antioxidant treatments showed slight drops in wall thickness, with 
Chitocurc, Lipids, Alb/CCM, and CCM showing 14%, 13%, 8%, and 12% decreases in wall 
thickness compared to Rad Sal. This would imply that all treatments provided some protective 
effect. When testing TGF-β1 appearance in the heart, the Alb/CCM treatment showed a decrease 
in TGF-β1 levels which would correspond with less fibrosis and the thinner right ventricles that 
were measured. Overall, these results show a small effect from all antioxidant treatments to 
mitigate the effects of radiation, with Alb/CCM showing the most effects. 
Left Ventricle:  For the cardiac muscle area per nuclei analysis, there was not a statistical 
difference between any of the antioxidant treatment groups and Rad Sal. For the wall thickness 
analysis, there was a significant effect between the treatment groups and Rad Sal. The radiation 
appeared to cause left ventricular thinning, and the Alb/CCM and CCM antioxidant treatments 
seemed to prevent this thinning, with increased in wall thickness. One explanation for the 
thinning could be stiffening of the vasculature prior to the left ventricle, since the aorta is not the 
only vessel that can be affected by radiation but was the only vessel investigated here. This work 
didn’t measure stiffness but noted increased wall thickness and collagen content that could result 
in stiffening of the aorta. For the TGF-β1 testing, there was a decrease in TGF-β1 levels in the 
Alb/CCM treatment. Overall, these results show an ability on the part of Alb/CCM and CCM 
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treatments to mitigate the effects of radiation induced cardiovascular damage in the left ventricle, 
especially Alb/CCM. 
Overall:  
The mice in this study were sacrificed two weeks after radiation. At that time point, the 
mice still appeared healthy, and did not have obvious signs of radiation damage. Based on 
literature, it is likely that a longer post-radiation study would have been indicated more 
conclusive radiation-induced cardiovascular damage. The significant effects shown as a result of 
radiation were a decrease in cardiac muscle per nuclei in the right ventricle and thickening of the 
right ventricle. Notable trends were also observed as a result of radiation, with thickening of the 
aortas and thinning of the left ventricle. These trends could have been more significant if larger 
sample sizes were used. The low amount of significant results reported here mirrors a paper by 
Heselich et al. in which heavy ion radiation (both titanium and iron) was used, and significant 
effects were not seen, indicating that single doses of radiation and short post-radiation sacrifices 
result in  fewer significant observable effects [51]. In the Heselich paper, radiation led to DNA 
damage and a reduction of S-phase cells in cell cultures, hindering proliferation. Within 24 hours 
these cell cultures were able to repair DNA and recover S-phase cell levels, demonstrating that 
for radiation to cause long term effects it may need to be given repeatedly or over extended 
periods of time more like what happens in space.   
Of the radiation effects noted here, Alb/CCM was the drug delivery vehicle that had a 
significant effect in mitigating changes in the left ventricle thickness. All of the treatments had 
some helpful effects, especially in reducing the changes in ventricular wall thickness, but 




There is inherent variability between mice, and this could not be eliminated because each 
mouse could only be given one of the drug delivery mechanisms. The mice could also not be 
tested before and after the radiation, since the tests required the mice to be sacrificed. As a result, 
the natural, pre-radiation differences between the mice could not be factored in to the study.  
Another limitation was that the radiation dose administered to the mice was low, and 
cardiovascular diseases take time to develop. While some studies have shown doses as low as 50 
cGy having an effect, most studies referenced here have used doses from 1-5 Gy [11, 27, 51]. A 
higher dose would likely show a more significant effect.  The purpose of this work was to 
examine the effects of radiation exposure during spaceflight, thus a low dose of radiation was 
selected to mimic the small doses of radiation that astronauts are exposed to over the time of 
space travel. The mice were also sacrificed after two weeks which may not have been enough 
time for fibrosis to be observed. 
Future Work:  
 Future work would include testing at higher doses of 56Fe radiation and/or waiting longer 
periods of time before sacrifice of the mice to investigate long term. A higher sample size would 
be necessary for the different assays to determine significant effects from radiation exposure. 
Future work would also investigate the thinning of the left ventricle and any resulting 
cardiovascular disease resulting from it. Future work would also include trying antioxidants 
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APPENDIX A: STATISTICS 
Student t tests 
Aortic Outgrowth 
Two-Sample T-Test and CI: Saline Outgrowth, Saline Treatments 
Method 
μ₁: mean of Saline Outgrowth when Saline Treatments = nr sal 
µ₂: mean of Saline Outgrowth when Saline Treatments = rad sal 
Difference: μ₁ - µ₂ 
Equal variances are not assumed for this analysis. 
Descriptive Statistics: Saline Outgrowth 
Saline 
Treatments N Mean StDev SE Mean 
nr sal 5 5847 4786 2140 
rad sal 7 7649 4552 1721 
Estimation for Difference 
Difference 
95% CI for 
Difference 
-1802 (-8135, 4530) 
Test 
Null hypothesis H₀: μ₁ - µ₂ = 0 
Alternative hypothesis H₁: μ₁ - µ₂ ≠ 0 
T-Value DF P-Value 
-0.66 8 0.530 
ROS ASSAY 
Two-Sample T-Test and CI: Saline ROS, Saline Treatments 
Method 
μ₁: mean of Saline ROS when Saline Treatments = NR Sal 
µ₂: mean of Saline ROS when Saline Treatments = Rad Sal 
Difference: μ₁ - µ₂ 
Equal variances are not assumed for this analysis. 




Treatments N Mean StDev SE Mean 
NR Sal 2 0.0548 0.0244 0.017 
Rad Sal 3 0.04817 0.00580 0.0033 
Estimation for Difference 
Difference 
95% CI for 
Difference 
0.0066 (-0.2167, 0.2299) 
Test 
Null hypothesis H₀: μ₁ - µ₂ = 0 
Alternative hypothesis H₁: μ₁ - µ₂ ≠ 0 
T-Value DF P-Value 




Two-Sample T-Test and CI: Saline Muscle Tissue/Nuclei ... ents 
Aorta 
Method 
μ₁: mean of Saline Muscle Tissue/Nuclei Aor when Saline Treatments Aorta = NR sal 
µ₂: mean of Saline Muscle Tissue/Nuclei Aor when Saline Treatments Aorta = Rad sal 
Difference: μ₁ - µ₂ 
Equal variances are not assumed for this analysis. 
Descriptive Statistics: Saline Muscle Tissue/Nuclei Aor 
Saline 
Treatments 
Aorta N Mean StDev 
SE 
Mean 
NR sal 2 204.6 23.0 16 
Rad sal 3 191.7 57.3 33 
Estimation for Difference 
Difference 
95% CI for 
Difference 




Null hypothesis H₀: μ₁ - µ₂ = 0 
Alternative hypothesis H₁: μ₁ - µ₂ ≠ 0 
T-Value DF P-Value 
0.35 2 0.760 
 
Right Ventricle 
Two-Sample T-Test and CI: Saline Muscle 
Tissue/Nuclei ... atments RV 
Method 
μ₁: mean of Saline Muscle Tissue/Nuclei RV when Saline Treatments RV = NR Sal 
µ₂: mean of Saline Muscle Tissue/Nuclei RV when Saline Treatments RV = Rad Sal 
Difference: μ₁ - µ₂ 
Equal variances are not assumed for this analysis. 
Descriptive Statistics: Saline Muscle Tissue/Nuclei RV 
Saline 
Treatments 
RV N Mean StDev 
SE 
Mean 
NR Sal 5 396.7 37.7 17 
Rad Sal 4 332.3 36.6 18 
Estimation for Difference 
Difference 
95% CI for 
Difference 
64.4 (3.6, 125.2) 
Test 
Null hypothesis H₀: μ₁ - µ₂ = 0 
Alternative hypothesis H₁: μ₁ - µ₂ ≠ 0 
T-Value DF P-Value 






Two-Sample T-Test and CI: Saline Muscle 
Tissue/Nuclei ... atments LV 
Method 
μ₁: mean of Saline Muscle Tissue/Nuclei LV when Saline Treatments LV = NR Sal 
µ₂: mean of Saline Muscle Tissue/Nuclei LV when Saline Treatments LV = Rad Sal 
Difference: μ₁ - µ₂ 
Equal variances are not assumed for this analysis. 
Descriptive Statistics: Saline Muscle Tissue/Nuclei LV 
Saline 
Treatments 
LV N Mean StDev 
SE 
Mean 
NR Sal 5 322.0 40.9 18 
Rad Sal 4 302.8 50.1 25 
Estimation for Difference 
Difference 
95% CI for 
Difference 
19.2 (-60.5, 99.0) 
Test 
Null hypothesis H₀: μ₁ - µ₂ = 0 
Alternative hypothesis H₁: μ₁ - µ₂ ≠ 0 
T-Value DF P-Value 




Two-Sample T-Test and CI: Saline Thickness Aorta, Saline ... ents 
Aorta 
Method 
μ₁: mean of Saline Thickness Aorta when Saline Treatments Aorta = NR sal 
µ₂: mean of Saline Thickness Aorta when Saline Treatments Aorta = Rad Sal 
Difference: μ₁ - µ₂ 
Equal variances are not assumed for this analysis. 
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Descriptive Statistics: Saline Thickness Aorta 
Saline 
Treatments 
Aorta N Mean StDev SE Mean 
NR sal 2 58.583 0.353 0.25 
Rad Sal 3 81.6 24.1 14 
Estimation for Difference 
Difference 
95% CI for 
Difference 
-23.0 (-82.7, 36.8) 
Test 
Null hypothesis H₀: μ₁ - µ₂ = 0 
Alternative hypothesis H₁: μ₁ - µ₂ ≠ 0 
T-Value DF P-Value 
-1.66 2 0.240 
 
Right Ventricle 
Two-Sample T-Test and CI: Saline Thickness RV, Saline 
Treatments RV 
Method 
μ₁: mean of Saline Thickness RV when Saline Treatments RV = NR Sal 
µ₂: mean of Saline Thickness RV when Saline Treatments RV = Rad Sal 
Difference: μ₁ - µ₂ 
Equal variances are not assumed for this analysis. 
Descriptive Statistics: Saline Thickness RV 
Saline 
Treatments 
RV N Mean StDev 
SE 
Mean 
NR Sal 5 867.6 38.7 17 
Rad Sal 4 999.6 67.9 34 




95% CI for 
Difference 
-132.0 (-237.8, -26.2) 
Test 
Null hypothesis H₀: μ₁ - µ₂ = 0 
Alternative hypothesis H₁: μ₁ - µ₂ ≠ 0 
T-Value DF P-Value 
-3.47 4 0.026 
 
Left Ventricle 
Two-Sample T-Test and CI: Saline Thickness LV, Saline 
Treatments LV 
Method 
μ₁: mean of Saline Thickness LV when Saline Treatments LV = NR Sal 
µ₂: mean of Saline Thickness LV when Saline Treatments LV = Rad Sal 
Difference: μ₁ - µ₂ 
Equal variances are not assumed for this analysis. 
Descriptive Statistics: Saline Thickness LV 
Saline 
Treatments 
LV N Mean StDev SE Mean 
NR Sal 5 1714 561 251 
Rad Sal 4 1333 543 271 
Estimation for Difference 
Difference 
95% CI for 
Difference 
381 (-524, 1285) 
Test 
Null hypothesis H₀: μ₁ - µ₂ = 0 
Alternative hypothesis H₁: μ₁ - µ₂ ≠ 0 
T-Value DF P-Value 





Two-Sample T-Test and CI: Adventitia Thickness ... rta Thickness 
Radia 
Method 
μ₁: mean of Adventitia Thickness Radiation when Treatment Aorta Thickness Radia = NR Sal 
µ₂: mean of Adventitia Thickness Radiation when Treatment Aorta Thickness Radia = Rad Sal 
Difference: μ₁ - µ₂ 
Equal variances are not assumed for this analysis. 




Radia N Mean StDev SE Mean 
NR Sal 2 10.42 6.76 4.8 
Rad Sal 3 16.32 9.27 5.4 
Estimation for Difference 
Difference 
95% CI for 
Difference 
-5.90 (-36.78, 24.98) 
Test 
Null hypothesis H₀: μ₁ - µ₂ = 0 
Alternative hypothesis H₁: μ₁ - µ₂ ≠ 0 
T-Value DF P-Value 
-0.82 2 0.498 
 
Two-Sample T-Test and CI: %Adventitia of total ... rta Thickness 
Radia 
Method 
μ₁: mean of %Adventitia of total thicknes_1 when Treatment Aorta Thickness Radia = NR Sal 
µ₂: mean of %Adventitia of total thicknes_1 when Treatment Aorta Thickness Radia = Rad 
Sal 
Difference: μ₁ - µ₂ 
Equal variances are not assumed for this analysis. 
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Radia N Mean StDev SE Mean 
NR Sal 2 15.09 8.46 6.0 
Rad Sal 3 18.00 4.84 2.8 
Estimation for Difference 
Difference 
95% CI for 
Difference 
-2.91 (-86.78, 80.97) 
Test 
Null hypothesis H₀: μ₁ - µ₂ = 0 
Alternative hypothesis H₁: μ₁ - µ₂ ≠ 0 
T-Value DF P-Value 
-0.44 1 0.736 
 
Two-Sample T-Test and CI: Saline % collagen Aorta, ... eatments 
Aorta 
Method 
μ₁: mean of Saline % collagen Aorta when Saline Treatments Aorta = NR Sal 
µ₂: mean of Saline % collagen Aorta when Saline Treatments Aorta = Rad Sal 
Difference: μ₁ - µ₂ 
Equal variances are not assumed for this analysis. 
Descriptive Statistics: Saline % collagen Aorta 
Saline 
Treatments 
Aorta N Mean StDev SE Mean 
NR Sal 2 8.82 7.81 5.5 
Rad Sal 3 10.839 0.246 0.14 
Estimation for Difference 
Difference 




-2.02 (-72.23, 68.18) 
Test 
Null hypothesis H₀: μ₁ - µ₂ = 0 
Alternative hypothesis H₁: μ₁ - µ₂ ≠ 0 
T-Value DF P-Value 
-0.37 1 0.777 
 
Right Ventricle 
Two-Sample T-Test and CI: Saline % collagen RV, 
Saline ... atments RV 
Method 
μ₁: mean of Saline % collagen RV when Saline Treatments RV = NR Sal 
µ₂: mean of Saline % collagen RV when Saline Treatments RV = Rad Sal 
Difference: μ₁ - µ₂ 
Equal variances are not assumed for this analysis. 
Descriptive Statistics: Saline % collagen RV 
Saline 
Treatments 
RV N Mean StDev SE Mean 
NR Sal 3 0.370 0.312 0.18 
Rad Sal 3 0.537 0.100 0.058 
Estimation for Difference 
Difference 
95% CI for 
Difference 
-0.167 (-0.981, 0.646) 
Test 
Null hypothesis H₀: μ₁ - µ₂ = 0 
Alternative hypothesis H₁: μ₁ - µ₂ ≠ 0 
T-Value DF P-Value 





Two-Sample T-Test and CI: Saline %collagen LV, Saline 
Treatments LV 
Method 
μ₁: mean of Saline %collagen LV when Saline Treatments LV = NR Sal 
µ₂: mean of Saline %collagen LV when Saline Treatments LV = Rad Sal 
Difference: μ₁ - µ₂ 
Equal variances are not assumed for this analysis. 
Descriptive Statistics: Saline %collagen LV 
Saline 
Treatments 
LV N Mean StDev SE Mean 
NR Sal 3 0.3326 0.0687 0.040 
Rad Sal 3 0.332 0.137 0.079 
Estimation for Difference 
Difference 
95% CI for 
Difference 
0.0005 (-0.3797, 0.3808) 
Test 
Null hypothesis H₀: μ₁ - µ₂ = 0 
Alternative hypothesis H₁: μ₁ - µ₂ ≠ 0 
T-Value DF P-Value 





Two-Sample T-Test and CI: Saline intensity Aorta, Saline ... ents 
Aorta 
Method 
μ₁: mean of Saline intensity Aorta when Saline Treatments Aorta = NR Sal 
µ₂: mean of Saline intensity Aorta when Saline Treatments Aorta = Rad Sal 
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Difference: μ₁ - µ₂ 
Equal variances are not assumed for this analysis. 
Descriptive Statistics: Saline intensity Aorta 
Saline 
Treatments 
Aorta N Mean StDev SE Mean 
NR Sal 2 1080704 509583 360329 
Rad Sal 2 2750209 3208276 2268593 
Estimation for Difference 
Difference 
95% CI for 
Difference 
-1669505 (-30856057, 27517047) 
Test 
Null hypothesis H₀: μ₁ - µ₂ = 0 
Alternative hypothesis H₁: μ₁ - µ₂ ≠ 0 
T-Value DF P-Value 




Two-Sample T-Test and CI: Saline intensity RV, Saline 
Treatments RV 
Method 
μ₁: mean of Saline intensity RV when Saline Treatments RV = NR Sal 
µ₂: mean of Saline intensity RV when Saline Treatments RV = Rad Sal 
Difference: μ₁ - µ₂ 
Equal variances are not assumed for this analysis. 
Descriptive Statistics: Saline intensity RV 
Saline 
Treatments 
RV N Mean StDev SE Mean 
NR Sal 3 15042834 7031889 4059863 
Rad Sal 3 14385768 7641902 4412054 
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Estimation for Difference 
Difference 
95% CI for 
Difference 
657066 (-18424005, 19738136) 
Test 
Null hypothesis H₀: μ₁ - µ₂ = 0 
Alternative hypothesis H₁: μ₁ - µ₂ ≠ 0 
T-Value DF P-Value 
0.11 3 0.920 
 
Left Ventricle 
Two-Sample T-Test and CI: Saline intensity LV, Saline 
Treatments LV 
Method 
μ₁: mean of Saline intensity LV when Saline Treatments LV = NR Sal 
µ₂: mean of Saline intensity LV when Saline Treatments LV = Rad Sal 
Difference: μ₁ - µ₂ 
Equal variances are not assumed for this analysis. 
Descriptive Statistics: Saline intensity LV 
Saline 
Treatments 
LV N Mean StDev SE Mean 
NR Sal 3 11797218 3392385 1958594 
Rad Sal 3 18299003 11281558 6513410 
Estimation for Difference 
Difference 
95% CI for 
Difference 
-6501784 (-35766341, 22762773) 
Test 
Null hypothesis H₀: μ₁ - µ₂ = 0 
Alternative hypothesis H₁: μ₁ - µ₂ ≠ 0 
T-Value DF P-Value 
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-0.96 2 0.440 
 
 
t-test summaries Aorta Right Ventricle Left Ventricle 
Aortic Outgrowth 0.530 NA  NA 
ROS Assay 0.772 NA NA 
H and E 0.760 0.041 0.562 
Thickness  0.240 0.026 0.343 
Massons Trichrome 0.777 0.469 0.996 




General Linear Model: Radiated Outgrowth versus ... iated 
Treatments 
Method 
Factor coding (-1, 0, +1) 
Factor Information 
Factor Type Levels Values 
Radiated Treatments Fixed 5 Alb_ccm, ccm, chitocurc, lipids, rad sal 
Analysis of Variance 
Source DF Adj SS Adj MS F-Value P-Value 
  Radiated Treatments 4 98948860 24737215 1.80 0.160 
Error 26 358205879 13777149       
Total 30 457154739          
Model Summary 
S R-sq R-sq(adj) R-sq(pred) 




Term Coef SE Coef T-Value P-Value VIF 
Constant 7192 668 10.77 0.000    
Radiated Treatments                
  Alb_ccm 3120 1350 2.31 0.029 1.72 
  ccm -1423 1350 -1.05 0.302 1.72 
  chitocurc -2118 1350 -1.57 0.129 1.72 




= 7192 + 3120 Radiated Treatments_Alb_ccm 
- 1423 Radiated Treatments_ccm 
- 2118 Radiated Treatments_chitocurc - 37 Radiated Treatments_lipids 
+ 457 Radiated Treatments_rad sal 
Fits and Diagnostics for Unusual Observations 
Obs 
Radiated 
Outgrowth Fit Resid 
Std 
Resid  
4 12625 5074 7551 2.23 R 
R  Large residual 




Comparisons for Radiated Outgrowth 
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Tukey Pairwise Comparisons: Radiated Treatments 
Grouping Information Using the Tukey Method and 90% Confidence 
Radiated 
Treatments N Mean Grouping 
Alb_ccm 6 10312.5 A 
rad sal 7 7649.3 A 
lipids 6 7155.0 A 
ccm 6 5769.2 A 
chitocurc 6 5074.1 A 
Means that do not share a letter are significantly different. 
Tukey Simultaneous Tests for Differences of Means 







90% CI T-Value 
Adjusted 
P-Value 
ccm - Alb_ccm -4543 2143 (-10104, 1018) -2.12 0.242 
chitocurc - Alb_ccm -5238 2143 (-10800, 323) -2.44 0.135 
lipids - Alb_ccm -3157 2143 (-8719, 2404) -1.47 0.588 
rad sal - Alb_ccm -2663 2065 (-8022, 2696) -1.29 0.700 
chitocurc - ccm -695 2143 (-6256, 4866) -0.32 0.997 
lipids - ccm 1386 2143 (-4175, 6947) 0.65 0.966 
rad sal - ccm 1880 2065 (-3479, 7239) 0.91 0.890 
lipids - chitocurc 2081 2143 (-3480, 7642) 0.97 0.866 
rad sal - chitocurc 2575 2065 (-2784, 7934) 1.25 0.725 
rad sal - lipids 494 2065 (-4865, 5853) 0.24 0.999 
Individual confidence level = 98.47% 
 
ROS ASSAY 
General Linear Model: Radiated ROS versus Radiated 
Treatments 
Method 
Factor coding (-1, 0, +1) 
Factor Information 
Factor Type Levels Values 
Radiated Treatments Fixed 4 Alb/CCM, Chitocurc, Lipids, Rad Sal 
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Analysis of Variance 
Source DF Adj SS Adj MS F-Value P-Value 
  Radiated Treatments 3 0.000318 0.000106 0.46 0.719 
Error 7 0.001617 0.000231       
Total 10 0.001935          
Model Summary 
S R-sq R-sq(adj) R-sq(pred) 
0.0151971 16.45% 0.00% 0.00% 
Coefficients 
Term Coef SE Coef T-Value P-Value VIF 
Constant 0.04460 0.00478 9.33 0.000    
Radiated Treatments                
  Alb/CCM 0.00115 0.00719 0.16 0.878 1.55 
  Chitocurc -0.01035 0.00898 -1.15 0.287 1.71 




= 0.04460 + 0.00115 Radiated Treatments_Alb/CCM 
- 0.01035 Radiated Treatments_Chitocurc 
+ 0.00565 Radiated Treatments_Lipids 
+ 0.00356 Radiated Treatments_Rad Sal 
Fits and Diagnostics for Unusual Observations 
Obs 
Radiated 
ROS Fit Resid 
Std 
Resid  
9 0.07600 0.04575 0.03025 2.30 R 




Comparisons for Radiated ROS 
Tukey Pairwise Comparisons: Radiated Treatments 
Grouping Information Using the Tukey Method and 95% Confidence 
Radiated 
Treatments N Mean Grouping 
Lipids 2 0.0502500 A 
Rad Sal 3 0.0481667 A 
Alb/CCM 4 0.0457500 A 
Chitocurc 2 0.0342500 A 
Means that do not share a letter are significantly different. 
 
Tukey Simultaneous Tests for Differences of Means 







95% CI T-Value 
Adjusted 
P-Value 
Chitocurc - Alb/CCM -0.0115 0.0132 (-0.0551, 0.0321) -0.87 0.818 
Lipids - Alb/CCM 0.0045 0.0132 (-0.0391, 0.0481) 0.34 0.985 
Rad Sal - Alb/CCM 0.0024 0.0116 (-0.0360, 0.0408) 0.21 0.997 
Lipids - Chitocurc 0.0160 0.0152 (-0.0343, 0.0663) 1.05 0.726 
Rad Sal - Chitocurc 0.0139 0.0139 (-0.0320, 0.0598) 1.00 0.753 
Rad Sal - Lipids -0.0021 0.0139 (-0.0480, 0.0438) -0.15 0.999 






General Linear Model: Radiation Muscle Tissue/Nucle_2 ... ents 
Aorta 
Method 
Factor coding (-1, 0, +1) 
Factor Information 
Factor Type Levels Values 
Radiation Treatments Aorta Fixed 5 Alb_CCM, CCM, Chitocurc, Lipids, Rad sal 
Analysis of Variance 
Source DF Adj SS Adj MS F-Value P-Value 
  Radiation Treatments Aorta 4 6452 1613 0.99 0.454 
Error 10 16230 1623       
Total 14 22682          
Model Summary 
S R-sq R-sq(adj) R-sq(pred) 
40.2871 28.44% 0.00% 0.00% 
Coefficients 
Term Coef SE Coef T-Value P-Value VIF 
Constant 198.7 10.7 18.64 0.000    
Radiation Treatments Aorta                
  Alb_CCM -6.2 24.5 -0.25 0.805 1.83 
  CCM 33.7 20.9 1.61 0.138 1.62 
  Chitocurc 8.6 18.9 0.45 0.660 1.53 
  Lipids -29.1 20.9 -1.39 0.195 1.62 
Regression Equation 
Radiation Muscle Tissue/Nucle_2 = 198.7 - 6.2 Radiation Treatments Aorta_Alb_CCM 
+ 33.7 Radiation Treatments Aorta_CCM 
+ 8.6 Radiation Treatments Aorta_Chitocurc 
- 29.1 Radiation Treatments Aorta_Lipids 




Comparisons for Radiation Muscle Tissue/Nucle_2 
Tukey Pairwise Comparisons: Radiation Treatments Aorta 
Grouping Information Using the Tukey Method and 75% Confidence 
Radiation 
Treatments 
Aorta N Mean Grouping 
CCM 3 232.403 A 
Chitocurc 4 207.250 A 
Alb_CCM 2 192.487 A 
Rad sal 3 191.690 A 
Lipids 3 169.596 A 
Means that do not share a letter are significantly different. 
Tukey Simultaneous Tests for Differences of Means 
Difference of Radiation 






75% CI T-Value 
Adjusted 
P-Value 
CCM - Alb_CCM 39.9 36.8 (-41.5, 121.3) 1.09 0.810 
Chitocurc - Alb_CCM 14.8 34.9 (-62.5, 92.0) 0.42 0.992 
Lipids - Alb_CCM -22.9 36.8 (-104.3, 58.5) -0.62 0.968 
Rad sal - Alb_CCM -0.8 36.8 (-82.2, 80.6) -0.02 1.000 
Chitocurc - CCM -25.2 30.8 (-93.3, 42.9) -0.82 0.919 
Lipids - CCM -62.8 32.9 (-135.6, 10.0) -1.91 0.372 
Rad sal - CCM -40.7 32.9 (-113.5, 32.1) -1.24 0.732 
Lipids - Chitocurc -37.7 30.8 (-105.8, 30.4) -1.22 0.739 
Rad sal - Chitocurc -15.6 30.8 (-83.7, 52.5) -0.51 0.985 
Rad sal - Lipids 22.1 32.9 (-50.7, 94.9) 0.67 0.958 
76 
 
Individual confidence level = 94.87% 
 
Right Ventricle 
General Linear Model: Radiation Muscle 
Tissue/Nuclei ... reatments RV 
Method 
Factor coding (-1, 0, +1) 
Factor Information 
Factor Type Levels Values 
Radiation Treatments RV Fixed 5 Alb/CCM, CCM, Chitocurc, Lipids, Rad Sal 
Analysis of Variance 
Source DF Adj SS Adj MS F-Value P-Value 
  Radiation Treatments RV 4 354.8 88.70 0.04 0.997 
Error 13 28970.4 2228.49       
Total 17 29325.2          
Model Summary 
S R-sq R-sq(adj) R-sq(pred) 
47.2069 1.21% 0.00% 0.00% 
Coefficients 
Term Coef SE Coef T-Value P-Value VIF 
Constant 339.8 11.2 30.23 0.000    
Radiation Treatments RV                
  Alb/CCM 1.4 21.5 0.07 0.948 1.65 
  CCM 2.3 23.9 0.10 0.925 1.78 
  Chitocurc 5.0 21.5 0.23 0.818 1.65 
  Lipids -1.3 23.9 -0.05 0.959 1.78 
Regression Equation 
Radiation Muscle Tissue/Nuclei = 339.8 + 1.4 Radiation Treatments RV_Alb/CCM 
+ 2.3 Radiation Treatments RV_CCM 
+ 5.0 Radiation Treatments RV_Chitocurc 
- 1.3 Radiation Treatments RV_Lipids 




Comparisons for Radiation Muscle Tissue/Nuclei 
Tukey Pairwise Comparisons: Radiation Treatments RV 
Grouping Information Using the Tukey Method and 75% Confidence 
Radiation 
Treatments RV N Mean Grouping 
Chitocurc 4 344.798 A 
CCM 3 342.053 A 
Alb/CCM 4 341.175 A 
Lipids 3 338.509 A 
Rad Sal 4 332.263 A 
Means that do not share a letter are significantly different. 
Tukey Simultaneous Tests for Differences of Means 
Difference of Radiation 






75% CI T-Value 
Adjusted 
P-Value 
CCM - Alb/CCM 0.9 36.1 (-77.4, 79.1) 0.02 1.000 
Chitocurc - Alb/CCM 3.6 33.4 (-68.8, 76.1) 0.11 1.000 
Lipids - Alb/CCM -2.7 36.1 (-80.9, 75.6) -0.07 1.000 
Rad Sal - Alb/CCM -8.9 33.4 (-81.4, 63.6) -0.27 0.999 
Chitocurc - CCM 2.7 36.1 (-75.5, 81.0) 0.08 1.000 
Lipids - CCM -3.5 38.5 (-87.2, 80.1) -0.09 1.000 
Rad Sal - CCM -9.8 36.1 (-88.1, 68.5) -0.27 0.999 
Lipids - Chitocurc -6.3 36.1 (-84.6, 72.0) -0.17 1.000 
Rad Sal - Chitocurc -12.5 33.4 (-85.0, 59.9) -0.38 0.995 
Rad Sal - Lipids -6.2 36.1 (-84.5, 72.0) -0.17 1.000 





General Linear Model: Radiation Muscle 
Tissue/Nucle_1 ... atments LV 
Method 
Factor coding (-1, 0, +1) 
Factor Information 
Factor Type Levels Values 
Radiation Treatments LV Fixed 5 Alb/CCM, CCM, Chitocurc, Lipids, Rad Sal 
Analysis of Variance 
Source DF Adj SS Adj MS F-Value P-Value 
  Radiation Treatments LV 4 6266 1566 1.22 0.347 
Error 14 18012 1287       
Total 18 24278          
Model Summary 
S R-sq R-sq(adj) R-sq(pred) 
35.8692 25.81% 4.61% 0.00% 
Coefficients 
Term Coef SE Coef T-Value P-Value VIF 
Constant 306.65 8.28 37.02 0.000    
Radiation Treatments LV                
  Alb/CCM -7.6 16.2 -0.47 0.644 1.63 
  CCM 35.4 16.2 2.19 0.046 1.63 
  Chitocurc -10.4 16.2 -0.64 0.532 1.63 
  Lipids -13.5 18.1 -0.75 0.467 1.76 
Regression Equation 
Radiation Muscle Tissue/Nucle_1 = 306.65 - 7.6 Radiation Treatments LV_Alb/CCM 
+ 35.4 Radiation Treatments LV_CCM 
- 10.4 Radiation Treatments LV_Chitocurc 
- 13.5 Radiation Treatments LV_Lipids 
- 3.9 Radiation Treatments LV_Rad Sal 





Tissue/Nucle_1 Fit Resid 
Std 
Resid  
5 364.2 296.3 67.9 2.19 R 
19 375.8 302.8 73.0 2.35 R 
R  Large residual 
Residual Plots for Radiation Muscle Tissue/Nucle_1 
 
 
Comparisons for Radiation Muscle Tissue/Nucle_1 
Tukey Pairwise Comparisons: Radiation Treatments LV 
Grouping Information Using the Tukey Method and 75% Confidence 
Radiation 
Treatments LV N Mean Grouping 
CCM 4 342.024 A 
Rad Sal 4 302.798 A 
Alb/CCM 4 299.012 A 
Chitocurc 4 296.286 A 
Lipids 3 293.140 A 
Means that do not share a letter are significantly different. 
Tukey Simultaneous Tests for Differences of Means 
Difference of Radiation 






75% CI T-Value 
Adjusted 
P-Value 
CCM - Alb/CCM 43.0 25.4 (-11.7, 97.7) 1.70 0.467 
Chitocurc - Alb/CCM -2.7 25.4 (-57.4, 52.0) -0.11 1.000 
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Lipids - Alb/CCM -5.9 27.4 (-65.0, 53.2) -0.21 0.999 
Rad Sal - Alb/CCM 3.8 25.4 (-50.9, 58.5) 0.15 1.000 
Chitocurc - CCM -45.7 25.4 (-100.4, 9.0) -1.80 0.409 
Lipids - CCM -48.9 27.4 (-108.0, 10.2) -1.78 0.419 
Rad Sal - CCM -39.2 25.4 (-93.9, 15.5) -1.55 0.552 
Lipids - Chitocurc -3.1 27.4 (-62.2, 55.9) -0.11 1.000 
Rad Sal - Chitocurc 6.5 25.4 (-48.2, 61.2) 0.26 0.999 
Rad Sal - Lipids 9.7 27.4 (-49.4, 68.7) 0.35 0.996 
Individual confidence level = 95.11% 
Thickness Measurements 
Aorta 
General Linear Model: Radiation Thickness Aorta versus ... ents 
Aorta 
Method 
Factor coding (-1, 0, +1) 
Factor Information 
Factor Type Levels Values 
Radiation Treatments Aorta Fixed 5 Alb CCM, CCM, chitocurc, Lipids, Rad Sal 
Analysis of Variance 
Source DF Adj SS Adj MS F-Value P-Value 
  Radiation Treatments Aorta 4 2374 593.4 0.90 0.501 
Error 10 6622 662.2       
Total 14 8995          
Model Summary 
S R-sq R-sq(adj) R-sq(pred) 
25.7323 26.39% 0.00% 0.00% 
Coefficients 
Term Coef SE Coef T-Value P-Value VIF 
Constant 71.06 6.81 10.44 0.000    
Radiation Treatments Aorta                
  Alb CCM -20.7 15.7 -1.33 0.214 1.83 
  CCM 16.1 13.4 1.20 0.257 1.62 
  chitocurc 5.0 12.1 0.41 0.690 1.53 
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  Lipids -10.8 13.4 -0.81 0.438 1.62 
Regression Equation 
Radiation Thickness Aorta = 71.06 - 20.7 Radiation Treatments Aorta_Alb CCM 
+ 16.1 Radiation Treatments Aorta_CCM 
+ 5.0 Radiation Treatments Aorta_chitocurc 
- 10.8 Radiation Treatments Aorta_Lipids 
+ 10.5 Radiation Treatments Aorta_Rad Sal 




Aorta Fit Resid 
Std 
Resid  
14 132.3 87.1 45.2 2.15 R 
R  Large residual 
 
Comparisons for Radiation Thickness Aorta 
Tukey Pairwise Comparisons: Radiation Treatments Aorta 
Grouping Information Using the Tukey Method and 80% Confidence 
Radiation 
Treatments 
Aorta N Mean Grouping 
CCM 3 87.1434 A 
Rad Sal 3 81.5788 A 
chitocurc 4 76.0221 A 
Lipids 3 60.2502 A 
Alb CCM 2 50.3127 A 
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Means that do not share a letter are significantly different. 
Tukey Simultaneous Tests for Differences of Means 
Difference of Radiation 






80% CI T-Value 
Adjusted 
P-Value 
CCM - Alb CCM 36.8 23.5 (-19.0, 92.6) 1.57 0.547 
chitocurc - Alb CCM 25.7 22.3 (-27.2, 78.7) 1.15 0.776 
Lipids - Alb CCM 9.9 23.5 (-45.9, 65.7) 0.42 0.992 
Rad Sal - Alb CCM 31.3 23.5 (-24.5, 87.1) 1.33 0.680 
chitocurc - CCM -11.1 19.7 (-57.8, 35.6) -0.57 0.977 
Lipids - CCM -26.9 21.0 (-76.8, 23.0) -1.28 0.708 
Rad Sal - CCM -5.6 21.0 (-55.5, 44.4) -0.26 0.999 
Lipids - chitocurc -15.8 19.7 (-62.5, 30.9) -0.80 0.924 
Rad Sal - chitocurc 5.6 19.7 (-41.1, 52.3) 0.28 0.998 
Rad Sal - Lipids 21.3 21.0 (-28.6, 71.2) 1.02 0.843 
Individual confidence level = 96.11% 
 
Right Ventricle 
General Linear Model: Radiation Thickness RV 
versus ... reatments RV 
Method 
Factor coding (-1, 0, +1) 
Factor Information 
Factor Type Levels Values 
Radiation Treatments RV Fixed 5 Alb CCM, CCM, Chitocurc, Lipids, Rad Sal 
Analysis of Variance 
Source DF Adj SS Adj MS F-Value P-Value 
  Radiation Treatments RV 4 50902 12725 0.89 0.497 
Error 14 200696 14335       
Total 18 251598          
Model Summary 
S R-sq R-sq(adj) R-sq(pred) 




Term Coef SE Coef T-Value P-Value VIF 
Constant 905.8 27.7 32.76 0.000    
Radiation Treatments RV                
  Alb CCM 13.0 54.0 0.24 0.814 1.63 
  CCM -25.9 54.0 -0.48 0.639 1.63 
  Chitocurc -47.5 54.0 -0.88 0.394 1.63 
  Lipids -33.5 60.3 -0.56 0.587 1.76 
Regression Equation 
Radiation Thickness RV = 905.8 + 13.0 Radiation Treatments RV_Alb CCM 
- 25.9 Radiation Treatments RV_CCM 
- 47.5 Radiation Treatments RV_Chitocurc 
- 33.5 Radiation Treatments RV_Lipids 
+ 93.9 Radiation Treatments RV_Rad Sal 
 
 
Comparisons for Radiation Thickness RV 
Tukey Pairwise Comparisons: Radiation Treatments RV 
Grouping Information Using the Tukey Method and 80% Confidence 
Radiation 
Treatments RV N Mean Grouping 
Rad Sal 4 999.646 A 
Alb CCM 4 918.745 A 
CCM 4 879.902 A 
Lipids 3 872.317 A 
Chitocurc 4 858.325 A 
Means that do not share a letter are significantly different. 
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Tukey Simultaneous Tests for Differences of Means 
Difference of Radiation 






80% CI T-Value 
Adjusted 
P-Value 
CCM - Alb CCM -38.8 84.7 (-234.0, 156.3) -0.46 0.990 
Chitocurc - Alb CCM -60.4 84.7 (-255.6, 134.7) -0.71 0.950 
Lipids - Alb CCM -46.4 91.4 (-257.2, 164.4) -0.51 0.985 
Rad Sal - Alb CCM 80.9 84.7 (-114.3, 276.1) 0.96 0.870 
Chitocurc - CCM -21.6 84.7 (-216.7, 173.6) -0.25 0.999 
Lipids - CCM -7.6 91.4 (-218.4, 203.2) -0.08 1.000 
Rad Sal - CCM 119.7 84.7 (-75.4, 314.9) 1.41 0.629 
Lipids - Chitocurc 14.0 91.4 (-196.8, 224.8) 0.15 1.000 
Rad Sal - Chitocurc 141.3 84.7 (-53.8, 336.5) 1.67 0.482 
Rad Sal - Lipids 127.3 91.4 (-83.5, 338.1) 1.39 0.642 
Individual confidence level = 96.30% 
 
Left Ventricle 
General Linear Model: Radiation Thickness LV 
versus ... Treatments LV 
Method 
Factor coding (-1, 0, +1) 
Factor Information 
Factor Type Levels Values 
Radiation Treatments LV Fixed 5 Alb CCM, CCM, Chitocurc, Lipids, Rad Sal 
Analysis of Variance 
Source DF Adj SS Adj MS F-Value P-Value 
  Radiation Treatments LV 4 3779759 944940 11.62 0.000 
Error 14 1138661 81333       
Total 18 4918420          
Model Summary 
S R-sq R-sq(adj) R-sq(pred) 




Term Coef SE Coef T-Value P-Value VIF 
Constant 1574.2 65.9 23.90 0.000    
Radiation Treatments LV                
  Alb CCM 496 129 3.86 0.002 1.63 
  CCM 576 129 4.48 0.001 1.63 
  Chitocurc -445 129 -3.46 0.004 1.63 
  Lipids -387 144 -2.69 0.017 1.76 
Regression Equation 
Radiation Thickness LV = 1574.2 + 496 Radiation Treatments LV_Alb CCM 
+ 576 Radiation Treatments LV_CCM 
- 445 Radiation Treatments LV_Chitocurc 
- 387 Radiation Treatments LV_Lipids 
- 241 Radiation Treatments LV_Rad Sal 




LV Fit Resid Std Resid  
2 805 1333 -528 -2.14 R 
19 2074 1333 741 3.00 R 
R  Large residual 
 
 
Comparisons for Radiation Thickness LV 
Tukey Pairwise Comparisons: Radiation Treatments LV 
Grouping Information Using the Tukey Method and 80% Confidence 
Radiation 
Treatments LV N Mean Grouping 
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CCM 4 2150.54 A    
Alb CCM 4 2070.66 A    
Rad Sal 4 1333.33    B 
Lipids 3 1187.62    B 
Chitocurc 4 1129.04    B 
Means that do not share a letter are significantly different. 
Tukey Simultaneous Tests for Differences of Means 
Difference of Radiation 






80% CI T-Value 
Adjusted 
P-Value 
CCM - Alb CCM 80 202 (-385, 545) 0.40 0.994 
Chitocurc - Alb CCM -942 202 (-1406, -477) -4.67 0.003 
Lipids - Alb CCM -883 218 (-1385, -381) -4.05 0.009 
Rad Sal - Alb CCM -737 202 (-1202, -272) -3.66 0.018 
Chitocurc - CCM -1022 202 (-1486, -557) -5.07 0.001 
Lipids - CCM -963 218 (-1465, -461) -4.42 0.004 
Rad Sal - CCM -817 202 (-1282, -352) -4.05 0.009 
Lipids - Chitocurc 59 218 (-444, 561) 0.27 0.999 
Rad Sal - Chitocurc 204 202 (-261, 669) 1.01 0.845 
Rad Sal - Lipids 146 218 (-356, 648) 0.67 0.960 




General Linear Model: Adventitia Thickness CCM 
versus ... ckness CCM 
Method 
Factor coding (-1, 0, +1) 
Factor Information 
Factor Type Levels Values 
Treatment Aorta Thickness CCM Fixed 5 Alb_CCM, CCM, Chitocurc, Lipids, Rad Sal 
Analysis of Variance 
Source DF Adj SS Adj MS F-Value P-Value 
  Treatment Aorta Thickness CCM 4 100.6 25.14 0.42 0.788 
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Error 9 534.5 59.39       
Total 13 635.1          
Model Summary 
S R-sq R-sq(adj) R-sq(pred) 
7.70652 15.83% 0.00% 0.00% 
Coefficients 
Term Coef SE Coef T-Value P-Value VIF 
Constant 15.01 2.09 7.19 0.000    
Treatment Aorta Thickness CCM                
  Alb_CCM -3.96 4.71 -0.84 0.422 1.84 
  CCM 4.08 4.03 1.01 0.338 1.64 
  Chitocurc 0.71 4.03 0.18 0.863 1.64 
  Lipids -2.14 4.03 -0.53 0.608 1.64 
Regression Equation 
Adventitia Thickness CCM = 15.01 - 3.96 Treatment Aorta Thickness CCM_Alb_CCM 
+ 4.08 Treatment Aorta Thickness CCM_CCM 
+ 0.71 Treatment Aorta Thickness CCM_Chitocurc 
- 2.14 Treatment Aorta Thickness CCM_Lipids 
+ 1.31 Treatment Aorta Thickness CCM_Rad Sal 





General Linear Model: %Adventitia of total thicknes_2 ... ickness 
CCM 
Method 
Factor coding (-1, 0, +1) 
Factor Information 
Factor Type Levels Values 
Treatment Aorta Thickness CCM Fixed 5 Alb_CCM, CCM, Chitocurc, Lipids, Rad Sal 
Analysis of Variance 
Source DF Adj SS Adj MS F-Value P-Value 
  Treatment Aorta Thickness CCM 4 67.70 16.93 0.38 0.819 
Error 9 402.66 44.74       
Total 13 470.36          
Model Summary 
S R-sq R-sq(adj) R-sq(pred) 
6.68883 14.39% 0.00% 0.00% 
Coefficients 
Term Coef SE Coef T-Value P-Value VIF 
Constant 19.71 1.81 10.88 0.000    
Treatment Aorta Thickness CCM                
  Alb_CCM -2.58 4.09 -0.63 0.544 1.84 
  CCM 3.80 3.50 1.09 0.306 1.64 
  Chitocurc 0.89 3.50 0.25 0.806 1.64 
  Lipids -0.40 3.50 -0.11 0.912 1.64 
Regression Equation 
%Adventitia of total thicknes_2 = 19.71 - 2.58 Treatment Aorta Thickness CCM_Alb_CCM 
+ 3.80 Treatment Aorta Thickness CCM_CCM 
+ 0.89 Treatment Aorta Thickness CCM_Chitocurc 
- 0.40 Treatment Aorta Thickness CCM_Lipids 
- 1.71 Treatment Aorta Thickness CCM_Rad Sal 




General Linear Model: Radiation % collagen Aorta versus ... ents 
Aorta 
Method 
Factor coding (-1, 0, +1) 
Factor Information 
Factor Type Levels Values 
Radiation Treatments Aorta Fixed 5 Alb_CCM, CCM, Chitocurc, Lipids, Rad Sal 
Analysis of Variance 
Source DF Adj SS Adj MS F-Value P-Value 
  Radiation Treatments Aorta 4 37.36 9.340 0.35 0.840 
Error 9 241.97 26.885       
Total 13 279.33          
Model Summary 
S R-sq R-sq(adj) R-sq(pred) 
5.18511 13.37% 0.00% 0.00% 
Coefficients 
Term Coef SE Coef T-Value P-Value VIF 
Constant 10.08 1.40 7.18 0.000    
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Radiation Treatments Aorta                
  Alb_CCM 0.79 3.17 0.25 0.809 1.84 
  CCM -3.08 2.71 -1.14 0.285 1.64 
  Chitocurc 1.41 2.71 0.52 0.616 1.64 
  Lipids 0.13 2.71 0.05 0.964 1.64 
Regression Equation 
Radiation % collagen Aorta = 10.08 + 0.79 Radiation Treatments Aorta_Alb_CCM 
- 3.08 Radiation Treatments Aorta_CCM 
+ 1.41 Radiation Treatments Aorta_Chitocurc 
+ 0.13 Radiation Treatments Aorta_Lipids 
+ 0.76 Radiation Treatments Aorta_Rad Sal 
 
 
Comparisons for Radiation % collagen Aorta 
Tukey Pairwise Comparisons: Radiation Treatments Aorta 
Grouping Information Using the Tukey Method and 95% Confidence 
Radiation 
Treatments 
Aorta N Mean Grouping 
Chitocurc 3 11.4870 A 
Alb_CCM 2 10.8664 A 
Rad Sal 3 10.8390 A 
Lipids 3 10.2058 A 
CCM 3 7.0003 A 
Means that do not share a letter are significantly different. 
Tukey Simultaneous Tests for Differences of Means 
Difference of Radiation 











CCM - Alb_CCM -3.87 4.73 (-19.80, 12.07) -0.82 0.919 
Chitocurc - Alb_CCM 0.62 4.73 (-15.31, 16.55) 0.13 1.000 
Lipids - Alb_CCM -0.66 4.73 (-16.59, 15.27) -0.14 1.000 
Rad Sal - Alb_CCM -0.03 4.73 (-15.96, 15.90) -0.01 1.000 
Chitocurc - CCM 4.49 4.23 (-9.76, 18.74) 1.06 0.822 
Lipids - CCM 3.21 4.23 (-11.04, 17.46) 0.76 0.937 
Rad Sal - CCM 3.84 4.23 (-10.41, 18.09) 0.91 0.887 
Lipids - Chitocurc -1.28 4.23 (-15.53, 12.97) -0.30 0.998 
Rad Sal - Chitocurc -0.65 4.23 (-14.90, 13.60) -0.15 1.000 
Rad Sal - Lipids 0.63 4.23 (-13.62, 14.88) 0.15 1.000 
Individual confidence level = 99.17% 
 
Right Ventricle 
General Linear Model: Radiation % collagen RV 
versus ... eatments RV 
Method 
Factor coding (-1, 0, +1) 
Factor Information 
Factor Type Levels Values 
Radiation Treatments RV Fixed 5 Alb_CCM, CCM, Chitocurc, Lipids, Rad Sal 
Analysis of Variance 
Source DF Adj SS Adj MS F-Value P-Value 
  Radiation Treatments RV 4 0.1234 0.03086 0.93 0.482 
Error 10 0.3302 0.03302       
Total 14 0.4537          
Model Summary 
S R-sq R-sq(adj) R-sq(pred) 
0.181727 27.21% 0.00% 0.00% 
Coefficients 
Term Coef SE Coef T-Value P-Value VIF 
Constant 0.3978 0.0469 8.48 0.000    
Radiation Treatments RV                
  Alb_CCM -0.0986 0.0938 -1.05 0.318 1.60 
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  CCM -0.0910 0.0938 -0.97 0.355 1.60 
  Chitocurc 0.0607 0.0938 0.65 0.532 1.60 
  Lipids -0.0103 0.0938 -0.11 0.915 1.60 
Regression Equation 
Radiation % collagen RV = 0.3978 - 0.0986 Radiation Treatments RV_Alb_CCM 
- 0.0910 Radiation Treatments RV_CCM 
+ 0.0607 Radiation Treatments RV_Chitocurc 
- 0.0103 Radiation Treatments RV_Lipids 
+ 0.1391 Radiation Treatments RV_Rad Sal 
Fits and Diagnostics for Unusual Observations 
Obs 
Radiation % 
collagen RV Fit Resid Std Resid  
5 0.077 0.459 -0.382 -2.57 R 
R  Large residual 
Residual Plots for Radiation % collagen RV 
 
 
Comparisons for Radiation % collagen RV 
Tukey Pairwise Comparisons: Radiation Treatments RV 
Grouping Information Using the Tukey Method and 95% Confidence 
Radiation 
Treatments RV N Mean Grouping 
Rad Sal 3 0.536940 A 
Chitocurc 3 0.458523 A 
Lipids 3 0.387557 A 
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CCM 3 0.306796 A 
Alb_CCM 3 0.299247 A 
Means that do not share a letter are significantly different. 
Tukey Simultaneous Tests for Differences of Means 
Difference of Radiation 






95% CI T-Value 
Adjusted 
P-Value 
CCM - Alb_CCM 0.008 0.148 (-0.480, 0.495) 0.05 1.000 
Chitocurc - Alb_CCM 0.159 0.148 (-0.329, 0.647) 1.07 0.816 
Lipids - Alb_CCM 0.088 0.148 (-0.400, 0.576) 0.60 0.973 
Rad Sal - Alb_CCM 0.238 0.148 (-0.250, 0.726) 1.60 0.528 
Chitocurc - CCM 0.152 0.148 (-0.336, 0.640) 1.02 0.840 
Lipids - CCM 0.081 0.148 (-0.407, 0.569) 0.54 0.980 
Rad Sal - CCM 0.230 0.148 (-0.258, 0.718) 1.55 0.556 
Lipids - Chitocurc -0.071 0.148 (-0.559, 0.417) -0.48 0.988 
Rad Sal - Chitocurc 0.078 0.148 (-0.409, 0.566) 0.53 0.982 
Rad Sal - Lipids 0.149 0.148 (-0.338, 0.637) 1.01 0.847 
Individual confidence level = 99.18% 
 
Left Ventricle 
General Linear Model: Radiation % collagen LV 
versus ... reatments LV 
Method 
Factor coding (-1, 0, +1) 
Factor Information 
Factor Type Levels Values 
Radiation Treatments LV Fixed 5 Alb_CCM, CCM, Chitocurc, Lipids, Rad Sal 
Analysis of Variance 
Source DF Adj SS Adj MS F-Value P-Value 
  Radiation Treatments LV 4 0.1182 0.02954 0.76 0.572 
Error 10 0.3861 0.03861       




S R-sq R-sq(adj) R-sq(pred) 
0.196501 23.43% 0.00% 0.00% 
Coefficients 
Term Coef SE Coef T-Value P-Value VIF 
Constant 0.3080 0.0507 6.07 0.000    
Radiation Treatments LV                
  Alb_CCM -0.147 0.101 -1.45 0.177 1.60 
  CCM 0.116 0.101 1.15 0.278 1.60 
  Chitocurc 0.045 0.101 0.45 0.665 1.60 
  Lipids -0.039 0.101 -0.38 0.712 1.60 
Regression Equation 
Radiation % collagen LV = 0.3080 - 0.147 Radiation Treatments LV_Alb_CCM 
+ 0.116 Radiation Treatments LV_CCM 
+ 0.045 Radiation Treatments LV_Chitocurc 
- 0.039 Radiation Treatments LV_Lipids 
+ 0.024 Radiation Treatments LV_Rad Sal 
Residual Plots for Radiation % collagen LV 
 
 
Comparisons for Radiation % collagen LV 
Tukey Pairwise Comparisons: Radiation Treatments LV 
Grouping Information Using the Tukey Method and 95% Confidence 
Radiation 
Treatments LV N Mean Grouping 
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CCM 3 0.424469 A 
Chitocurc 3 0.353318 A 
Rad Sal 3 0.332048 A 
Lipids 3 0.269450 A 
Alb_CCM 3 0.160688 A 
Means that do not share a letter are significantly different. 
Tukey Simultaneous Tests for Differences of Means 
Difference of Radiation 






95% CI T-Value 
Adjusted 
P-Value 
CCM - Alb_CCM 0.264 0.160 (-0.264, 0.791) 1.64 0.505 
Chitocurc - Alb_CCM 0.193 0.160 (-0.335, 0.720) 1.20 0.751 
Lipids - Alb_CCM 0.109 0.160 (-0.419, 0.636) 0.68 0.957 
Rad Sal - Alb_CCM 0.171 0.160 (-0.356, 0.699) 1.07 0.818 
Chitocurc - CCM -0.071 0.160 (-0.599, 0.456) -0.44 0.991 
Lipids - CCM -0.155 0.160 (-0.683, 0.373) -0.97 0.864 
Rad Sal - CCM -0.092 0.160 (-0.620, 0.435) -0.58 0.976 
Lipids - Chitocurc -0.084 0.160 (-0.611, 0.444) -0.52 0.983 
Rad Sal - Chitocurc -0.021 0.160 (-0.549, 0.506) -0.13 1.000 
Rad Sal - Lipids 0.063 0.160 (-0.465, 0.590) 0.39 0.994 




General Linear Model: Radiation intensity Aorta versus ... ments 
Aorta 
Method 
Factor coding (-1, 0, +1) 
Factor Information 
Factor Type Levels Values 
Radiation Treatments Aorta Fixed 5 Alb/CCM, CCM, Chitocurc, Lipids, Rad Sal 
Analysis of Variance 
Source DF Adj SS Adj MS F-Value P-Value 
  Radiation Treatments Aorta 4 5.79713E+13 1.44928E+13 0.35 0.832 
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Error 6 2.45015E+14 4.08359E+13       
Total 10 3.02987E+14          
Model Summary 
S R-sq R-sq(adj) R-sq(pred) 
6390297 19.13% 0.00% 0.00% 
Coefficients 
Term Coef SE Coef T-Value P-Value VIF 
Constant 3327839 1952268 1.70 0.139    
Radiation Treatments Aorta                
  Alb/CCM 487644 4007757 0.12 0.907 1.57 
  CCM -1166523 4007757 -0.29 0.781 1.57 
  Chitocurc 3773903 3461001 1.09 0.317 1.44 
  Lipids -2517394 4007757 -0.63 0.553 1.57 
Regression Equation 
Radiation intensity Aorta = 3327839 + 487644 Radiation Treatments Aorta_Alb/CCM 
- 1166523 Radiation Treatments Aorta_CCM 
+ 3773903 Radiation Treatments Aorta_Chitocurc 
- 2517394 Radiation Treatments Aorta_Lipids 
- 577630 Radiation Treatments Aorta_Rad Sal 




Aorta Fit Resid 
Std 
Resid  
3 18662829 7101742 11561087 2.22 R 
R  Large residual 





Comparisons for Radiation intensity Aorta 
Tukey Pairwise Comparisons: Radiation Treatments Aorta 
Grouping Information Using the Tukey Method and 80% Confidence 
Radiation 
Treatments 
Aorta N Mean Grouping 
Chitocurc 3 7101742 A 
Alb/CCM 2 3815483 A 
Rad Sal 2 2750209 A 
CCM 2 2161316 A 
Lipids 2 810446 A 
Means that do not share a letter are significantly different. 
Tukey Simultaneous Tests for Differences of Means 






Difference Simultaneous 80% CI T-Value 
Adjusted 
P-Value 
CCM - Alb/CCM -1654168 6390297 (-17876021, 
14567686) 
-0.26 0.999 
Chitocurc - Alb/CCM 3286259 5833516 (-11522199, 
18094717) 
0.56 0.976 
Lipids - Alb/CCM -3005038 6390297 (-19226891, 
13216816) 
-0.47 0.987 
Rad Sal - Alb/CCM -1065274 6390297 (-17287128, 
15156579) 
-0.17 1.000 
Chitocurc - CCM 4940427 5833516 (-9868032, 19748885) 0.85 0.906 





Rad Sal - CCM 588893 6390297 (-15632960, 
16810747) 
0.09 1.000 
Lipids - Chitocurc -6291297 5833516 (-21099755, 8517162) -1.08 0.812 
Rad Sal - Chitocurc -4351533 5833516 (-19159992, 
10456925) 
-0.75 0.937 
Rad Sal - Lipids 1939763 6390297 (-14282090, 
18161617) 
0.30 0.998 
Individual confidence level = 95.58% 
 
Right Ventricle 
General Linear Model: Radiation intensity RV 
versus ... Treatments RV 
Method 
Factor coding (-1, 0, +1) 
Factor Information 
Factor Type Levels Values 
Radiation Treatments RV Fixed 5 Alb/CCM, CCM, Chitocurc, Lipids, Rad Sal 
Analysis of Variance 
Source DF Adj SS Adj MS F-Value P-Value 
  Radiation Treatments RV 4 2.21318E+14 5.53294E+13 0.68 0.620 
Error 9 7.27715E+14 8.08572E+13       
Total 13 9.49033E+14          
Model Summary 
S R-sq R-sq(adj) R-sq(pred) 
8992066 23.32% 0.00% 0.00% 
Coefficients 
Term Coef SE Coef T-Value P-Value VIF 
Constant 15647420 2435063 6.43 0.000    
Radiation Treatments RV                
  Alb/CCM -6378645 5494243 -1.16 0.276 1.84 
  CCM 4745886 4701168 1.01 0.339 1.64 
  Chitocurc 4554662 4701168 0.97 0.358 1.64 




Radiation intensity RV = 15647420 - 6378645 Radiation Treatments RV_Alb/CCM 
+ 4745886 Radiation Treatments RV_CCM 
+ 4554662 Radiation Treatments RV_Chitocurc 
- 1660251 Radiation Treatments RV_Lipids 
- 1261652 Radiation Treatments RV_Rad Sal 
Residual Plots for Radiation intensity RV 
 
 
Comparisons for Radiation intensity RV 
Tukey Pairwise Comparisons: Radiation Treatments RV 
Grouping Information Using the Tukey Method and 95% Confidence 
Radiation 
Treatments RV N Mean Grouping 
CCM 3 20393306 A 
Chitocurc 3 20202082 A 
Rad Sal 3 14385768 A 
Lipids 3 13987169 A 
Alb/CCM 2 9268775 A 
Means that do not share a letter are significantly different. 
Tukey Simultaneous Tests for Differences of Means 
Difference of Radiation 




Difference Simultaneous 95% CI T-Value 
Adjusted 
P-Value 





Chitocurc - Alb/CCM 10933307 8208595 (-16695415, 
38562029) 
1.33 0.680 
Lipids - Alb/CCM 4718394 8208595 (-22910328, 
32347116) 
0.57 0.976 
Rad Sal - Alb/CCM 5116993 8208595 (-22511729, 
32745715) 
0.62 0.967 
Chitocurc - CCM -191224 7341991 (-24903104, 
24520656) 
-0.03 1.000 
Lipids - CCM -6406137 7341991 (-31118017, 
18305743) 
-0.87 0.900 
Rad Sal - CCM -6007538 7341991 (-30719418, 
18704343) 
-0.82 0.918 
Lipids - Chitocurc -6214913 7341991 (-30926793, 
18496967) 
-0.85 0.909 
Rad Sal - Chitocurc -5816314 7341991 (-30528194, 
18895567) 
-0.79 0.927 
Rad Sal - Lipids 398599 7341991 (-24313281, 
25110480) 
0.05 1.000 
Individual confidence level = 99.17% 
 
Left Ventricle 
General Linear Model: Radiation intensity LV 
versus ... Treatments LV 
Method 
Factor coding (-1, 0, +1) 
Factor Information 
Factor Type Levels Values 
Radiation Treatments LV Fixed 5 Alb/CCM, CCM, Chitocurc, Lipids, Rad Sal 
Analysis of Variance 
Source DF Adj SS Adj MS F-Value P-Value 
  Radiation Treatments LV 4 9.96928E+13 2.49232E+13 0.26 0.894 
Error 9 8.52235E+14 9.46927E+13       
Total 13 9.51927E+14          
Model Summary 
S R-sq R-sq(adj) R-sq(pred) 




Term Coef SE Coef T-Value P-Value VIF 
Constant 17239085 2635173 6.54 0.000    
Radiation Treatments LV                
  Alb/CCM -5791102 5945751 -0.97 0.356 1.84 
  CCM 1399552 5087503 0.28 0.789 1.64 
  Chitocurc 433044 5087503 0.09 0.934 1.64 
  Lipids 2898589 5087503 0.57 0.583 1.64 
Regression Equation 
Radiation intensity LV = 17239085 - 5791102 Radiation Treatments LV_Alb/CCM 
+ 1399552 Radiation Treatments LV_CCM 
+ 433044 Radiation Treatments LV_Chitocurc 
+ 2898589 Radiation Treatments LV_Lipids 
+ 1059917 Radiation Treatments LV_Rad Sal 
 
 
Comparisons for Radiation intensity LV 
Tukey Pairwise Comparisons: Radiation Treatments LV 
Grouping Information Using the Tukey Method and 95% Confidence 
Radiation 
Treatments LV N Mean Grouping 
Lipids 3 20137674 A 
CCM 3 18638637 A 
Rad Sal 3 18299003 A 
Chitocurc 3 17672130 A 
Alb/CCM 2 11447984 A 
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Means that do not share a letter are significantly different. 
Tukey Simultaneous Tests for Differences of Means 
Difference of Radiation 




Difference Simultaneous 95% CI T-Value 
Adjusted 
P-Value 
CCM - Alb/CCM 7190653 8883165 (-22708553, 
37089860) 
0.81 0.921 
Chitocurc - Alb/CCM 6224146 8883165 (-23675061, 
36123353) 
0.70 0.951 
Lipids - Alb/CCM 8689690 8883165 (-21209517, 
38588897) 
0.98 0.859 
Rad Sal - Alb/CCM 6851019 8883165 (-23048188, 
36750226) 
0.77 0.933 
Chitocurc - CCM -966507 7945344 (-27709171, 
25776156) 
-0.12 1.000 
Lipids - CCM 1499037 7945344 (-25243627, 
28241701) 
0.19 1.000 
Rad Sal - CCM -339634 7945344 (-27082298, 
26403029) 
-0.04 1.000 
Lipids - Chitocurc 2465544 7945344 (-24277119, 
29208208) 
0.31 0.998 
Rad Sal - Chitocurc 626873 7945344 (-26115790, 
27369537) 
0.08 1.000 
Rad Sal - Lipids -1838671 7945344 (-28581335, 
24903993) 
-0.23 0.999 
Individual confidence level = 99.17% 
 
ANOVA summaries Aorta Right Ventricle Left Ventricle 
Aortic Outgrowth 0.160 NA  NA 
ROS Assay 0.719 NA NA 
H and E 0.454 0.997 0.347 
Thickness  0.501 0.497 <0.001 
Massons Trichrome 0.840 0.482 0.572 
Immunohistology 0.832 0.620 0.894 
 
 
 
